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Abstract 
 
Control of cell proliferation is greatly diminished in cancer cells.  In order to understand 
how to prevent the uncontrolled proliferation of cancer cells, it is first important to 
understand how cells normally control proliferation.  Stathmin, a microtubule regulatory 
protein, is over-expressed in many cancers and required for survival of several cancer 
lines. In a study of breast cancer cell lines, Alli et al. (Oncogene. 26:1003-12) proposed 
that stathmin is required for survival of cells lacking p53, but this hypothesis was not 
tested directly. Here we tested their hypothesis by examining cell survival in cells 
depleted of stathmin, p53 or both proteins. Comparing HCT116 colon cancer cell lines 
differing in TP53 genotype, stathmin depletion resulted in significant cell cycle delay and 
death only in cells lacking p53. As a second experimental system, we compared the 
effects of stathmin depletion from HeLa cells, which normally lack detectable levels of 
p53 due to expression of the HPV E6 protein. Stathmin depletion caused a large 
percentage of HeLa cells to both delay in the cell cycle and then die via apoptosis. 
Restoring p53, by depletion of HPV E6, rescued HeLa cells from stathmin-depletion 
induced delay and death. The stathmin-dependent survival of cells lacking p53 was not 
confined to cancerous cells because both proteins were required for survival of normal 
human fibroblasts. 
 
P53 and stathmin depletion leads to a G2 cell cycle delay, however, it is still unclear as to 
why we see this synergy.  We hypothesize that stathmin depletion relays a signal via 
stabilization of the microtubule cytoskeleton, specifically in cells lacking p53. 
 2 
Alternatively, stathmin could have a function separate from its microtubule regulatory 
activity, and loss of this additional function could lead to cell cycle delay. As a test of our 
hypothesis, we examined whether microtubule stability is greatest in cells lacking both 
stathmin and p53.  Results showed that HeLa cells depleted of both stathmin and p53 
showed a large increase in both acetylated microtubule content (a marker of microtubule 
stability) and rate of microtubule nucleation.  Restoring p53 in stathmin-depleted cells 
reduces both the amount of acetylated microtubules and the microtubule nucleation rate.  
To further test the link between stathmin depletion in cells lacking p53 and microtubules, 
the microtubule network was manipulated by either nocodazole-dependent 
depolymerization or by restoring the microtubule network to control levels by over-
expressing stathmin truncations (full-length stathmin or stathmin Δ101-149).  Both of 
these treatments allowed cells to escape the G2 delay, while over-expression of a 
stathmin truncation that does not affect the microtubule array (stathmin Δ5-25) did not 
affect the G2 delay. 
 
Our results demonstrate that stathmin is required for cell survival in cells lacking p53, 
suggesting that stathmin depletion could be used therapeutically to induce a G2 cell cycle 
delay and apoptosis in tumors without functional p53.  Our results also indicate that the 
interphase microtubule cytoskeleton is a novel target for control of cell proliferation, 
particularly for the greater than 50% of human cancers that lack p53 because of either 
inactivating mutations or viral infection.  Together the results described in this 
dissertation could lead to new methods to treat and kill cancer cells that specifically lack 
p53, while leaving healthy cells relatively unaffected. 
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Chapter 1:  Introduction 
 
Researchers have been trying to find a cure for cancer for decades.  The American Cancer 
Society estimates cancers affect 11.7 million people in the United States alone (in 2007), 
but to date treatments have many side effects and are not effective against certain types of 
cancers.  On a cellular level, cancers can and do have mutations to genes encoding many 
different proteins that affect numerous cellular pathways.  Cancer cells that lack the p53 
protein, for example, are among the most malignant and lethal, and account for about 
fifty percent of all human cancers (Wallace-Brodeur and Lowe, 1999). These types of 
cancer cells can no longer repair damaged DNA, or send apoptotic signals if the damage 
is beyond repair. 
 
Alli et al (2007) and others have suggested that depleting stathmin from cells lacking p53  
can lead to apoptosis, bypassing the natural role of p53 in apoptotic signaling.  However, 
apoptotic death by stathmin depletion is only correlated with p53 status; it is not yet clear 
whether p53 must be absent for stathmin depletion to induce cell death.  If the Alli et al 
(2007) hypothesis is correct, how does stathmin depletion accomplish the reactivation of 
the apoptotic-signaling pathway?  Could stathmin’s effects on the microtubule network, 
and therefore the microtubule network itself, be important in this signaling pathway?  By 
answering these questions we can open up new avenues for possible advancements in 
finding novel targets for cancer therapies.  These questions are addressed in this 
dissertation.  The following sections introduce the critical cellular components and 
processes studied during the dissertation research. 
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Cytoskeleton 
Actin filaments (F-actin), intermediate filaments (IF), and microtubules (MTs) make up 
the cytoskeleton of a eukaryotic cell.  These components work together to affect and 
establish many of the cell’s characteristics, including maintaining its shape, creating 
polarity, and allowing motility.  Although these filaments work together to form the 
whole of the cytoskeleton network, each has its own specific responsibilities in the cell.  
MTs in particular are responsible for cell division, vesicle trafficking, and cell movement 
via flagella.  These processes all require the MT arrays within the cell to be both dynamic 
and static, depending on the function to which each array is being used.  The nucleation 
(formation) rates and relative dynamics must therefore be controlled at all times. 
Microtubule-associating proteins (MAPs) function to create, maintain, and destroy the 
various MT arrays that are present in the cell in order to regulate the dynamics. 
 
Microtubule Structure 
The structure of a microtubule is an essential part of what allows these filaments to 
function as they do in cells.  Each filament is made of thirteen protofilaments that are 
noncovalently linked together to form the microtubule (Desai and Mitchison, 1997). 
These protofilaments connect together to form a hollow tube (Aldaz et al., 2005) with a 
25nm diameter, and a 14nm gap in the center (Figure 1.1a). The tubulin dimer’s ability to 
form longitudinal, as well as lateral bonds (Meurer-Grob et al., 2001; Nogales, 2000), and 
its unique shape gives the filament its sturdy (McGrath, 2006), yet flexible characteristic 
that makes it optimal for producing arrays that can bend but not break (Figure 1.1a).  
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Each protofilament is made of heterodimers of alpha tubulin (α-tb) and beta tubulin (β-
tb) that connect together in a head-to-tail fashion to form the protofilament (Meurer-Grob 
et al., 2001). Although they are never found in their monomeric form, both α-tb and β-tb 
have a molecular weight of approximately 50 kDa, and are 451 and 442 amino acids in 
length, respectively (McKean et al., 2001). 
 
Microtubule Dynamics 
The heterodimeric properties of these filaments allow for them to have polarity.  In this 
case, the α-tb is exposed at the “minus” end, while the β-tb is exposed at the “plus” end 
(Mitchison, 1993).  Polarity forms because of the head to tail alignment of the dimers.  
The GTP bound to α-tb is trapped in the heterodimer and is therefore non-exchangeable 
and unable to hydrolyze. The GTP on the β-tb, on the other hand, is able to rapidly 
hydrolyze GTP to GDP making the dimer’s connection with the other heterodimers 
unstable (Mitchison, 1993; Nogales et al., 1998).  It is the β-tb bound GTP that gives 
MTs their dynamic nature.  This fragile stability is what allows for the rapid dissociation 
of these structures.  As long as a GTP is bound to β-tb, each protofilament will remain 
straight and stiff (Meurer-Grob et al., 2001).  When GTP is hydrolyzed to GDP at the MT 
tip, the protofilament begins to bend and the protofilaments fray apart (Figure 1.1b).  The 
loss of tb-GTP allows for the lateral connections to be disturbed causing the filament to 
depolymerize (Aldaz et al., 2005).  In order to prevent this depolymerization, the tubulin 
subunits that are most recently added retain their GTP and form a “GTP cap” (Erickson 
and O'Brien, 1992). The GTP that is not at the end of the filament can be hydrolyzed, 
while the presence of a GTP cap at the plus end of the MT allows each protofilament to 
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remain in a straight conformation trapping the rest of the MT together despite the reduced 
strength of the lateral bonds between protofilaments (Figure 1.1c).  Without this cap, the 
MT is no longer stable and cannot grow longer.  Therefore, polymerization can only 
occur in the presence of the GTP cap.  Tubulin subunits are added and lost from the plus 
end of the MT much faster than they are from the minus end (Moritz et al., 1995; 
Vorobjev et al., 1999).  The gain and loss of a GTP cap is what allows the MT to quickly 
shift from a growth phase to a shortening phase and vice versa, in a process known as 
dynamic instability (Mitchison and Kirschner, 1984).  The loss of the protective GTP cap 
leads to a rapid switch between growth and shortening, known as a catastrophe.  A rescue 
event can occur if the MT stops shortening and begins to grow again.  The exact 
mechanism of how these switches occur is not well understood.  All that is known is that 
the GTP cap must be reformed if growth is to occur and must be lost for shortening to 
begin. 
 
Assembly of Microtubules 
Microtubules can self-assemble at a slow rate in vitro depending on tb concentration.  
However, this process produces very unstable microtubules.  Tubulin starts to polymerize 
into small fragments, but cannot remain in a polymerized form until the polymer becomes 
larger and more stable.  Once a stable protofilament starts to form, which can take a long 
time, elongation can finally occur.  After elongation begins, MTs quickly move towards a 
state where the proportion of free tubulin to MT polymer is constant.  In animal cells, the 
assembly of MTs is not a spontaneous process unless tubulin concentration is high 
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enough; therefore growing MTs usually require other proteins to assemble properly 
(Moritz et al., 1995). 
 
In vivo, assembly needs to be much more controlled and nucleation needs to be much 
faster.  For this to happen, minus ends of MTs are bound to γ-tubulin ring complexes 
(γTuRCs).  γ-tubulin ring complexes are packed together in a highly organized complex 
called a microtubule organizing center (MTOC).  The MTOC contains γ TuRC, γ tubulin 
(γ-tb), a pair of centrioles, and many additional proteins (Desai and Mitchison, 1997; 
Dictenberg et al., 1998).  The MTOC forms a scaffold, where rapid MT nucleation 
occurs, since the dimers polymerize from the γ TuRC, and MTs radiate out into the cell.  
In mitosis, a centrosome (a MTOC) is at each spindle pole and allows MTs to radiate into 
the center and capture chromosomes.  Nucleation sites orient the dynamic plus end away 
from nucleation sites, while the minus end is always anchored to this site (Becker and 
Cassimeris, 2005).  In the life of any MT, multiple catastrophes and rescues events can 
frequently occur (Komarova et al., 2002).   
 
The MT network plays an important role in vesicle and chromosome trafficking in the 
cell as well.  The MT network is involved in transporting cargo into and out of the cell.  
Microtubule motor proteins, such as kinesin and dynein, attach to MTs and walk along 
the filament with its attached cargo (Hirokawa and Takemura, 2004; Vershinin et al., 
2008).  This cargo is then shuttled throughout the cell until it reaches its destination 
where the cargo is released from the motor protein. 
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The formation of a microtubule network throughout the cell also allows for MTs to play 
an essential role in cellular signaling.  Acetylation, for instance, is a marker of more 
stable MTs and leads to greater binding of kinesin motors.  These acetylated MTs are 
both remarkably stable and significantly less dynamic then other MTs.  The increased 
affinity of motors to acetylated MTs leads to a higher level of selective transport of 
vesicles throughout the cell (Bulinski, 2007; Reed et al., 2006).  Polyglutamylation of α-
tb was proposed to be important in the interaction of tb with MAPs (Edde et al., 1990; 
Kann et al., 2003).  Other modifications such as detyrosination, phosphorylation, and 
polyglucylation are suggested to play a role in stabilizing MTs (Gundersen et al., 1984; 
Lin et al., 2002).  Such post-translational modifications are also suggested to allow 
signals to be sent throughout the cell.  This signaling function could be accomplished by 
using the MTs as a scaffold from which other proteins can bind or be transported along 
the MT in order to propagate the signal (Bulinski, 2007; Larsson et al., 1999). 
 
Microtubule Associated Proteins (MAPs) 
Microtubule associated proteins (MAPs) are used to regulate assembly and either 
stabilize or destabilize the growing MT depending on the type of MAP that is active 
(Desai and Mitchison, 1997).  The activity states of these proteins determine the turnover 
rate of a given MT.  There are two general MAPs, those that stabilize MTs and those that 
destabilize them.  Certain MAPs act to destabilize MTs by binding to tubulin dimers, 
sequestering them away from the growing MTs, while other types of destabilizing MAPs 
can bind to the tip of growing protofilaments and halt dynamics and promote 
catastrophes.  MAPs can also act by binding along the side of the MT, both stabilizing 
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and cross linking them, or they can bind at the tips of the MTs promoting polymerization 
and further growth.  The more stabilizing MAPs that are present on a MT, the longer the 
MT will grow.  Many MAPs are activated or deactivated based on their phosphorylation 
state (Cassimeris and Spittle, 2001).  MAP phosphorylation sites allow for a 
conformational change in the protein depending on whether the site is phosphorylated or 
not. 
 
Drugs, such as paclitaxel (Taxol), can also stabilize the MT cytoskeleton.  Taxol 
stabilizes MTs and leads to accumulation of polymer in the cell, preventing the 
completion of mitosis, resulting in a block during M phase.  If the cell cycle is not 
allowed to continue, the cell will eventually begin apoptosis (Donaldson et al., 1994; 
Gascoigne and Taylor, 2009). 
 
Stathmin/Oncoprotein 18 
Stathmin/Oncoprotein 18 (STMN) is a MAP that destabilizes MTs (Belmont and 
Mitchison, 1996; Cassimeris and Spittle, 2001).  This 18 kDa (149 amino acid) protein 
functions to both sequester tubulin and promote catastrophes (Howell et al., 1999b; 
Larsson et al., 1999).  In vitro, at a pH of 6.8, stathmin binds and sequesters two tubulin 
dimers (Figure 1.2) forming a T2S complex and removes tubulin from the polymer-
forming tubulin pool (Cassimeris, 2002).  While at a higher pH (7.5), stathmin promotes 
catastrophes possibly by attaching to a growing MT end (Howell et al., 1999a).  
Truncated versions of this protein show that the N-terminal sequence of stathmin is 
important for catastrophe promoting function.  While the C-terminal sequence is 
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responsible for sequestering tubulin (Clement et al., 2005; Howell et al., 1999a; Howell 
et al., 1999b).  Larsson et al (1999) showed that the C-terminal sequence activity of the 
stathmin protein is not required to disrupt the MT network in cells. 
 
Stathmin is active in its unphosphorylated state.  However, stathmin has four serine 
residues (S16, S25, S38, and S63) that can be phosphorylated (Cassimeris, 2002).  The  
tubulin binding efficiency in vitro of this MAP decreases with the addition of phosphate 
groups and is completely off during mitosis when it is fully phosphorylated (Larsson et 
al., 1997; Larsson et al., 1995).  Phosphorylation at serine 16 and 63 causes stathmin to 
bind weakly to tubulin.  Phosphorylation at these sites suppresses stathmin to a much 
greater extent than at serine 25 and 38 (Cassimeris, 2002).  PKA, MAP kinases, and 
CDKs are just a few of the kinases that are responsible for phophorylating stathmin 
(Cassimeris and Spittle, 2001; Gradin et al., 1998; Marklund et al., 1996).  
 
Along with its role in MT destabilization, stathmin is also involved in cell signaling, 
however, with the exception of crosstalk with actin via MTs (Wittmann et al., 2004), this 
signaling is not well understood.  Despite the fact that little is known about this signaling 
function, it has been suggested that these signals play a pivotal role in both the cell cycle 
and cell differentiation (Sobel, 1991).  Stathmin has been shown to be a target of 
numerous signal cascades which lead to phosphorylation of stathmin, allowing both cell 
division and differentiation to occur (Sobel, 1991). 
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Recently stathmin has been shown to have additional sources of regulation that do not 
involve phosphorylation.  P27Kip1, a cyclin dependent kinase (CDK) inhibitor 
(Baldassarre et al., 2005), and STAT3, a transcription factor (Ng et al., 2006), have been 
shown to bind to stathmin's C-terminal amino acids (Baldassarre et al., 2005; Ng et al., 
2006).  Binding of STAT3 to stathmin has been shown to block the ability of stahmin to 
bind and destabilize MTs (Ng et al., 2006). The CKI, p27kip1 also binds stathmin's C-
terminus and inhibits its MT destabilizing activity (Baldassarre et al., 2005).  The binding 
of these proteins to stathmin suggests stathmin may play a greater role in signal 
transduction then was originally thought.  Both p27kip1 and STAT3 have also been 
implicated in tumor cell migration and therefore have important roles in metastasis and 
cancer progression (Baldassarre et al., 2005; Ng et al., 2006).   
 
Stathmin is overexpressed in many cancers. This phenotype exists in leukemia (Melhem 
et al., 1997), lymphoma (Nylander et al., 1995), multiple carcinomas (Kouzu et al., 2006; 
Nakashima et al., 2006; Nishio et al., 2001; Yuan et al., 2006),  adenocarcinoma (Chen et 
al., 2003; Friedrich et al., 1995), prostate cancer (Mistry et al., 2005), breast cancer 
(Bieche et al., 1998; Brattsand, 2000), and ovarian cancer (Price et al., 2000). Because 
stathmin is associated with so many cancers, stathmin targeted treatments have started to 
be considered for cancer therapies (Kouzu et al., 2006; Mistry et al., 2005).  Cancers 
where stathmin is overexpressed have a high malignancy phenotype, which leads to 
generally poor prognosis (Chen et al., 2003; Mistry et al., 2005). 
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The removal of stathmin from cells (or animals, such as mice) leads to organisms whose 
cell cycles seem normal throughout development.  At the cellular level, transient removal 
of stathmin leads to an increase in MT concentration (Holmfeldt et al., 2006; Howell et 
al., 1999b; Ringhoff and Cassimeris, 2009b; Sellin et al., 2008).  However, mice were 
stathmin has been knocked out produce viable embryos that mature and reproduce 
relatively normally (Schubart et al., 1996).  Although mice develop normally without 
stathmin, an age-dependent axonopathy of the central and perpheral nervous system does 
occur (Liedtke et al., 2002).  Stathmin also plays an essential role in regulating innate and 
learned fear in these mice (Shumyatsky et al., 2005), indicating that stathmin participates 
non-redundantly in spinal neuronal processes, but these processes are not sufficient to 
compromise viability in knockout mice. 
 
Recent research has shown that while the removal of stathmin from healthy cells has no 
effect on the cell cycle, the removal of stathmin from certain cancer cell lines leads to cell 
death within as little as 24-48 hours (Alli et al., 2007; Mistry et al., 2005; Wang et al., 
2007; Zhang et al., 2006).  In each study, a slowing of cell proliferation rate was observed 
prior to apoptosis, but the literature shows conflicting evidence over whether it is a G1 or 
G2/M block.  In either case, it has also been shown that this cell cycle block leads to an 
increase in apoptosis (Alli et al., 2007; Mistry et al., 2005; Zhang et al., 2006).  While the 
removal of stathmin causes apoptosis in some cancer cell lines, other cancer lines have 
shown no such phenotype.  Alli et al (2007) compared seven breast cancer cell lines 
differing in p53 status.  The five cancer lines that lacked functional p53 showed an 
increase in cells with 4N DNA content and induction of apoptosis when stathmin was 
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depleted.  However, these cancer cell lines have numerous other differences that could 
make them more susceptible to apoptosis due to stathmin depletion.  Also one of the plus-
p53 cell lines that did not die, MCF7, has a mutation in caspase 3, which would prevent 
apoptosis in this cell line.  A successful knockdown of stathmin in cells with wild type 
p53 was not included in their study.  Therefore, while it has been hypothesized that 
decreased stathmin level leads to apoptosis only in cells lacking p53, this hypothesis has 
not been tested directly (Alli et al., 2007).  We tested this hypothesis using matched 
cancer cell lines that only differ in their p53 status (Chapter 2). 
 
Cell Cycle 
In order for cells to grow and divide, they must proceed through the cell cycle.  During 
the cell cycle certain events, like chromosomal duplication, must happen at specific 
places at specific times.  Because of this, the processes of the cell cycle must be highly 
controlled.  In its simplest form the cell cycle consists of two stages: interphase, where 
the cell grows and replicates its DNA, and mitosis, where the cell divides creating two 
identical daughter cells.  Interphase consists of two gap (growth) phases, G1 and G2, 
which occur on either side of S phase, where DNA is replicated.  In order to transition 
from one stage to another, many conditions or checkpoints must be met.  The main 
controls of the cell cycle are a set of proteins called cyclins and cyclin-dependent kinases 
(CDKs).  During the cell cycle, the cyclin proteins fluctuate in abundance and depending 
on which cyclins are present, at any given time, they allow the cell to proceed from one 
stage to another by interacting with CDKs to phosphorylate a wide array of proteins 
involved in each step of the cycle. (Morgan, 1997) 
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For stathmin-depleted cells, the focus is primarily on the transition from G2 to M phase 
of the cell cycle.  Here, cyclin B levels rise significantly following DNA replication.  
Cyclin B binds CDK1, but is quickly made inactive by the inhibitory phosphoylation 
placed on CDK1, by Wee1, at two specific sites on the protein (Thr14 and Tyr15).  To 
further control the activity of CDK1, CAK adds an additional phosphorylation at Thr167, 
priming the complex for activation as soon as the inhibitory phosphorylation is removed.  
These phosphorylation events prevent entrance in mitosis until the cell is ready, the 
environment is favorable, and all the DNA has been replicated.  When all these 
checkpoints have been reached the inhibitory phosphorylation of CDK1 is reversed by 
the activity of Cdc25, which removes the phosphorylation and inactivates Wee1 activity, 
thereby activating the CDK1/cyclin B complex.  This kinase activation allows for the 
phosphorylation of many mitotic proteins and drives progression into mitosis.  If these 
checkpoints are not met the cell cycle will fail to progress until all necessary conditions 
have been met and satisfied. (Morgan, 1997) 
 
Apoptosis 
Organisms need their cells to be able to sacrifice themselves for the benefit of the whole 
organism.  Cells have developed a way to commit suicide or programmed cell death if 
their lack of health endangers the cells around it.  This process, apoptosis, involves 
complex pathways that terminate the cell if the damage cannot be repaired.  Cells have 
developed two specific mechanisms to transmit this death signal, an intrinsic and an 
extrinsic pathway. 
 15 
 
In the intrinsic pathway, DNA damage or absence of survival signals, such as growth 
factor or hormone, lead to the start of apoptosis.  As an example, if DNA damage is 
sensed by p53, the p53 protein is then activated.  P53 is activated by its release from 
MDM2, which is phosphorylated in response to the damage.  P53 then functions as a 
transcription factor and promotes the transcription of Bcl-2 proteins (such as Bax and 
Bad), which move to the mitochondria and disrupt its membrane.  This causes the 
mitochondria to release cytochrome c.  Cytochrome c binds with Apaf-1 and procaspase 
9 to form the apoptosome, the formation of this complex leads to the cleavage of 
procaspase 9 into the functional component Caspase 9.  Caspase 9 starts a cascade that 
activates caspase 3.  Caspase 3 releases CAD from the ICAD-CAD protein complex.  
CAD enters the nucleus and with the help of poly ADP ribose polymerase (PARP), which 
is cleaved by caspase 3, cleaves DNA and causes the cell to die (Figure 1.3b). (Elmore, 
2007) 
 
In the extrinsic pathway, an external source activates the apoptotic pathway.  As an 
example, a FAS ligand, released from a neighboring cell, binds to the FAS receptor of the 
apoptotic cell.  The binding of the FAS ligand activates the receptor, which is recruits and 
binds FADD.  This transmembrane protein complex cleaves procaspase 8 into the 
protein’s active form, caspase 8.  Caspase 8 then activates caspase 3, which then follows 
the same pathway as the intrinsic pathway leading to cellular death (Figure 1.3a). 
(Elmore, 2007) 
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Cancer cells must avoid apoptosis to survive and proliferate.  In order to survive, the 
pathways that would normally activate apoptosis in response to chromosomal defects and 
other cellular damage must be blocked (Elmore, 2007).  For example, cells with a 
mutation in p53 are more likely to proliferate because p53 normally halts the cell cycle 
until DNA damage is repaired (Elledge, 1996).  Therefore without functional p53, cells 
pass through the cell cycle even if there is significant damage to the DNA, allowing 
mutations to accumulate (Elledge, 1996). 
 
P53: a DNA damage checkpoint protein 
The tumor suppressor, p53, is a protein that responds to DNA damage.  When the protein 
is functioning normally, in a healthy cell, p53 is quickly bound to MDM2 and 
ubiquitinated and destroyed by the cell keeping its levels low (Caspari, 2000; Kelly and 
Brown, 2000).  However, if DNA damage occurs, a serine/threonine kinase (ATM or 
ATR) phosphorylates p53 (at serine 15) causing it to release from MDM2 and results in 
increased p53 levels (Caspari, 2000).  P53 then acts by initiating a pathway that stalls the 
cell cycle until repairs have been made or apoptosis begins.  If DNA has not yet been 
replicated (G1), once p53 is released it binds to the regulatory region of the p21 gene 
(Ahn et al., 1999).  This acts as a transcription factor, which leads it to increase the 
concentration of p21 (a cyclin dependent kinase inhibitor) protein in the cell (Figure 1.4).  
P21 acts by binding to an active cyclin/CDK complex and prevents it from advancing the 
cell cycle by causing a G1 arrest (Elledge, 1996; Kelly and Brown, 2000).  If the damage 
cannot be repaired, the cell will enter apoptosis, leading to cell death (Caspari, 2000).   
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In about fifty percent of cancers, p53 is malfunctioning in some way (Caspari, 2000; 
Hollstein et al., 1991).  Whether it is destroyed, sequestered, or just non-functional via a 
mutation, the inability of p53 to do its job can lead to numerous additional mutations or 
severe chromosomal alterations if the DNA is damaged.  Mutations in p53 can prevent it 
from releasing from MDM2 or making it otherwise ineffective.  The human 
papillomavirus, specifically, uses two viral proteins (E6 and E7 respectively) to sequester 
the host cell’s p53 and Rb, another protein that can halt the cell cycle.  The HPV E6 
protein binds to p53 and targets it for ubiquitination and destruction, thus reducing p53 
concentration to a very low level.  Koivosalo et al (2005; 2006) showed that by utilizing 
RNA interference against the E6 protein, it is possible to restore p53 in HeLa cells. 
 
Cells lacking functional p53 can no longer stop the cell cycle which leads to the damaged 
DNA being passed to the next generation before it can be repaired (Elledge, 1996).  
Cancers lacking p53 are some of the worst and have poor prognosis (Wallace-Brodeur 
and Lowe, 1999).  The reason for this poor prognosis is because once the DNA damage 
checkpoint is bypassed it leads to genomic instability and more mutations thereby 
causing the mutation rate to increase exponentially (Elledge, 1996). 
 
Dissertation Summary 
Chapter 2 explores whether or not the removal of stathmin from cancer cells only kills 
cancers that have a malfunctioning p53.  We showed that stathmin depletion both causes 
a G2 delay and apoptosis in a p53-independent manner.  We tested this by using two 
model systems; the first was a set of matched cancer cell lines, HCT116WTp53 and 
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HCT116p53-/-, in which one member lacks functional p53.  As a second system, we 
restored p53 to HeLa cells to see if we could reverse the phenotype.  Both models 
confirmed that both stathmin and p53 must be depleted for cells delay in G2 of the cell 
cycle and initiate apoptosis. 
 
Experiments in chapter 3 addresses stathmin’s specific role in the cell cycle delay 
pathway and determined if this signaling uses the microtubule network or stathmin’s 
other binding partners, p27kip1 and STAT3.  We showed that there is a significant 
difference in the MT networks of cancer cells where stathmin was depleted when p53 
was absent, when compared to the depletion of either protein alone. By destabilizing the 
MT network, we determined that changes to the MT cytoskeleton can bypass stathmin’s 
role in the pathway and that MTs are therefore required for the signal to be relayed.  
Using truncated versions of the stathmin protein, we further confirmed that stathmin 
relays a cell cycle delay signal using the MTs and that p27kip1 and/or STAT3 play little 
role, if any, in this signaling. 
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Figures: 
 
Figure 1.1:  Microtubule structure.  (A) A MT forms when 13 protofilaments align 
laterally to form a hollow tube.  Red dots represent the lateral and longitudinal bonds 
between adjacent tubulin dimers.  (B) When bonds between adjacent protofilaments are 
disturbed the MT frays and begins to lose stability.  (C) The loss of bonds associated with 
a fraying MT is due to the loss of the GTP-cap that is found on the end of a growing MT.  
When the GTP is hydrolyzed to GDP, the MT begins to depolymerize. 
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Figure 1.2:  Stathmin binding tubulin.  (A) A model of stathmin (black) binding to two 
tubulin heterodimers forming a T2S complex, thereby sequestering tubulin away from 
polymerizing MTs.  (B) A 3.5 Å resolution X-ray crystal structure of the stathmin domain 
of the related protein, RB3, binding to two tubulin heterodimers (Steinmetz, 2007). 
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Figure 1.3:  Apoptosis signaling pathway.  (A) The extrinsic apoptotic pathway begins 
when an external source signals a cell to die.  A signal enters the cell via cell-cell 
communication. The signal causes procaspase 8 to be cleaved to form caspase 8, which 
starts a signal cascade leading to apoptosis.  (B) The intrinsic apoptotic pathway begins 
when an internal signal is detected (such as DNA damage).  This signal leads the eventual 
disturbance of the mitochondrial inner membrane causing the release of cytochrome c.  
Cytochrome c forms a complex with procaspase 9 and Apaf-1, which causes the cleavage 
of procaspase 9 to caspase 9.  Caspase 9 starts a signaling cascade leading to apoptosis. 
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Figure 1.4:  p53’s role in the cell.  Under normal conditions, p53 is immediately bound 
by MDM2 and marked for destruction by ubiquitin.  This ubiquitinated protein is sent to 
the proteosome where it is degraded.  When DNA damage occurs p53 is phosphorylated 
and released from mdm2.  p53 then moves to the nucleus where it acts as a transcription 
factor for many different genes (p21 is shown as an example).  These genes cause cell 
cycle arrest while DNA damage is repaired or can cause the cell to begin apoptosis. 
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Chapter 2 
 
 
Stathmin/Oncoprotein 18, a microtubule regulatory protein, is required 
for survival of both normal and cancer cell lines lacking the tumor 
suppressor, p53 
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Introduction 
 
Microtubules are dynamic polymers of α/ß tubulin dimer subunits that contribute to a 
number of cell processes including chromosome movement and mitosis. Several 
successful chemotherapies, including paclitaxel and vinblastine, are thought to act by 
targeting microtubules or their tubulin subunits, disrupting mitotic spindle function, 
activating the spindle assembly checkpoint and inducing cell death (Jordan and Kamath, 
2007; Rieder and Maiato, 2004; Weaver and Cleveland, 2005). While microtubules have 
been a successful target for chemotherapy development (Jordan and Kamath, 2007), 
accessory proteins that regulate microtubule assembly and disassembly are also targets 
for novel chemotherapeutics (Bhat and Setaluri, 2007; Chin and Herbst, 2006). Of these 
regulatory proteins, stathmin/oncoprotein 18, a microtubule destabilizing protein, has 
received attention recently as a potential target for cancer therapy (Kouzu et al., 2006; 
Mistry et al., 2005; Rana et al., 2008). 
 
Stathmin is overexpressed in many cancers including leukemia (Melhem et al., 1997), 
lymphoma (Nylander et al., 1995), oral squamous-cell (Kouzu et al., 2006), adenoid 
cystic (Nakashima et al., 2006), lung (Nishio et al., 2001), and hepatocellular carcinomas 
(Yuan et al., 2006), adenocarcinoma (Chen et al., 2003; Friedrich et al., 1995), prostate 
cancer (Mistry et al., 2005), sarcomas (Belletti et al., 2008), glioma (Ngo et al., 2007), 
breast cancer (Bieche et al., 1998; Brattsand, 2000), and ovarian cancer (Price et al., 
2000). Cancers where stathmin is overexpressed have been shown to have a high 
malignancy phenotype, which leads to generally poor prognosis, supporting the use of 
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stathmin expression as a biomarker for cancer stage progression (Chen et al., 2003; 
Mistry et al., 2005).  
 
While stathmin level may serve as a biomarker in many cancers, several studies have 
demonstrated that stathmin depletion may also have therapeutic value; in a number of 
cancer cell lines stathmin depletion results in cell cycle arrest and apoptosis. Mistry et al. 
(Mistry et al., 2005) found that expression of anti-stathmin ribozymes depleted stathmin 
and resulted in apoptosis in the androgen-independent prostate cancer cell line LNCaP. 
Depletion of stathmin by siRNA or shRNA in HeLa cells (Zhang et al., 2006), 
osteosarcoma cell lines (Wang et al., 2007) and several breast cancer cell lines (Alli et al., 
2007) also demonstrated reduced cell proliferation and apoptosis after stathmin reduction. 
In contrast to these cancer cell lines, stathmin knockout mice are viable (Schubart et al., 
1996). These results have raised interest in stathmin reduction as a potential cancer 
therapy, possibly active only in cancerous cells. 
 
It is currently not known why even partial stathmin depletion is sufficient to induce 
apoptosis in several cancer cell lines. Most studies have indicated that stathmin depletion 
results in a G2/M block (Mistry et al., 2005; Wang et al., 2009; Zhang et al., 2006), but 
normally stathmin is inactivated by phosphorylation at entry into mitosis (Larsson et al., 
1997; Larsson et al., 1995; Marklund et al., 1996) and does not have a detectable 
microtubule destabilizing activity during mitosis (Ringhoff and Cassimeris, 2009b). 
These latter data strongly suggest that stathmin depletion does not lead to apoptosis by 
inducing a mitotic block. An alternative mechanism was suggested by Alli et al. (Alli et 
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al., 2007), who noted that those cell lines requiring stathmin for survival also expressed 
mutant p53. This intriguing hypothesis was not tested directly because Alli et al. (Alli et 
al., 2007) were unable to deplete stathmin from cell lines expressing wildtype p53. 
Further complicating analysis, some of the breast cancer cell lines used by Alli et al. (Alli 
et al., 2007) have additional mutations targeting other tumor suppressor genes, including 
Rb and PTEN (DeGraffenried et al., 2004; Wang et al., 1993). 
 
Here we used several experimental systems to test whether stathmin is specifically 
required for survival of those cells lacking p53. First, we compared cell proliferation and 
death after stathmin depletion from matched colon cancer cell lines (HCT116) differing 
in p53 genotype. As an alternate approach, we restored p53 to HeLa cells by depletion of 
the human papillomavirus (HPV) E6 protein, which normally binds p53 and marks it for 
destruction. Finally, we depleted stathmin and/or p53 from normal human foreskin 
fibroblasts (HFF cells) to address whether stathmin is specifically required for cancer cell 
survival. We found that stathmin is required for the survival of both cancerous and non-
cancerous derived cell lines, but only in the absence of p53.  In cells lacking both 
stathmin and p53, cells arrest or delay at G2 of the cell cycle.  
 
Methods 
 
Cell Culture:  
Cells were grown at 37ºC in a humidified atmosphere of 5% CO2.  HCT116 and HFF 
cells were grown in DMEM (GIBCO) supplemented with 3.7g/L sodium bicarbonate, 1X 
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antibiotic/antimycotic (Sigma), 1% sodium pyruvate, and 10% fetal bovine serum (FBS) 
(GIBCO-Invitrogen).  HeLa cells were grown in MEM (GIBCO) supplemented with 
2.2g/L sodium bicarbonate, 1X antibiotic/antimycotic, and 10% FBS. 
 
Drugs:   
Doxorubicin was added to cells to induce DNA damage and stabilize p53, facilitating its 
detection by western blot. When used, doxorubicin (0.5 µM) was added to cells for the 
last 24 hours of an experimental treatment. Doxorubicin was never used in experiments to 
measure cell proliferation or cell death. Some cells were treated with the caspase 
inhibitor, Z-VAD-FMK (10 µm; Sigma-Aldrich) or DMSO as a vehicle control. Z-VAD-
FMK was added to cells 24 hours prior to any other treatment and remained for the 
duration of the experiment. 
 
RNA interference and shRNA transfections:  
RNA interference (RNAi) was achieved using GeneSilencer reagents following the 
manufacturer’s protocol. Cells were grown on 35 mm dishes for 1-2 days before the 
addition of siRNA. Cells were serum starved 30 minutes pre-transfection and 4 hours 
post-transfection to improve transfection efficiency. RNAi oligonucleotides (Dharmacon) 
used included: SMTN1 (Op18-443),  5’- CGUUUGCGAGAGAAGGAUAdtdt-
3’(Holmfeldt et al., 2007) and HPV E6 (18E6-385),  5’-
CUAACACUGGGUUAUACAAdtdt-3’ (Koivusalo et al., 2005).  SiGlo Risc-Free 
siRNA (Dharmacon) was used as a control siRNA sequence for these experiments. A 
stathmin shRNA plasmid and control plasmid were obtained from Superarray Bioscience 
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Corporation and used to confirm results from siRNA.  Cells were grown similarly to 
those treated with RNAi except that Fugene 6 was used to transfect cells with shRNA 
plasmids.  The shRNA (manufacturer's #4) used recognizes 607-627 of exon 4 of the 
stathmin gene. Some cells were also transfected with TransSilent empty vector or 
TransSilent p53 shRNA plasmids (Panomics;(Giono and Manfredi, 2007)) using Fugene 
6 (Piehl and Cassimeris, 2003; Warren et al., 2006). 
 
Cell growth and death measurements:  
Cells were grown for 1-5 days post-transfection with siRNA or shRNA, trypsinized, 
stained with Trypan Blue (0.4%) and counted using a hemocytometer.  Cell viability was 
assessed by Trypan Blue exclusion. Live and dead cells were counted, averaged and 
pooled for 3 separate experiments for each cell line and treatment. Data shown are means 
± standard deviations. 
 
Groups of cells were also followed over time by plating cells on grid-etched coverslips 
attached to the bottoms of 35 mm dishes (MatTek Corporation). Cells were plated and 
incubated for 24 hrs before transfection of siRNAs. Cells were allowed to grow for an 
additional 24 hrs and then observed using a 20X objective on an inverted microscope 
(Nikon TE2000E) equipped with phase contrast optics and MetaVu image acquisition 
software.  Ten grid squares were chosen randomly and images were acquired from these 
squares each day for up to 5 days. Three separate imaging time course experiments were 
performed and representative images are shown in Figures 2.1 and 2.3. 
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Statistical analysis of cell counts, including those determined after immunofluorescent 
staining (below), were performed using Paired t-tests in Microsoft Excel or GraphPad 
Software (www.graphpad.com/quickcalcs/ttest1.cfm). 
 
Indirect Immunofluorescence and confocal microscopy:   
Cells were fixed and imaged as described previously (Piehl and Cassimeris, 2003).  
Primary antibodies used were mouse monoclonal α-tubulin (B512; Sigma-Aldrich), 
rabbit anti-TPX2 (Garrett et al., 2002) (Gift from Duane Compton, Dartmouth Medical 
School), rabbit anti-cyclin B1 (Sigma-Aldrich), rabbit anti-phospho-CDK1 (Tyr 15) (Cell 
Signaling Technology) and mouse anti-cleaved PARP (ASP214) (Cell Signaling 
Technology). Goat anti-mouse or rabbit Alexa Fluor 488 or 563 (Invitrogen) were used as 
the secondary antibodies in these experiments. Confocal microscopy was used to image 
stained cells as described previously (Warren et al., 2006).  Images were acquired using a 
40X/1.3NA objective.  Image stacks were converted to maximum intensity projections, 
exported as TIFF files and assembled using Photoshop.  
 
Protein Isolation and Western Blotting:   
Soluble cell extracts were prepared for SDS-polyacrylamide gel electrophoresis as 
described previously (Ringhoff and Cassimeris, 2009b).  Protein concentrations were 
measured by Bradford assay (Bradford, 1976). Membranes were probed and imaged as 
previously described (Ringhoff and Cassimeris, 2009b) using primary antibodies mouse 
anti-p53 (Vision Bio Systems), rabbit anti-stathmin (Sigma-Aldrich), or rabbit anti-actin 
(Sigma-Aldrich) followed by goat anti-mouse or rabbit horseradish peroxidase-linked 
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IgG (Sigma-Aldrich). Protein depletions were estimated by comparison of western blot 
signals to those generated by serial dilution of the control-treated cell lysate. 
 
Results 
 
Depletion of stathmin from HCT116 colon cancer cell lines 
To test directly whether p53 is required for survival of cells depleted of stathmin, we used 
HCT116 colon cancer cell lines differing in TP53 genotype. The HCT116p53 -/- line was 
developed by knocking out both copies of the TP53 gene from the parental HCT116 line 
(HCT116WTp53; (Bunz et al., 1998)). We first examined the extent and time course of 
stathmin depletion after siRNA transfection, compared to cells transfected with siGlo, a 
non-targeting control siRNA (Dharmacon). For HCT116p53-/- cells, stathmin was depleted 
by approximately 75% within 24 hours after transfection and remained low for 5 days 
(Figure 2.1A). We found that stathmin depletion was more difficult in HCT116WTp53, 
consistent with a previous study of breast cancer cell lines (Alli et al., 2007).  By 72 hrs 
after siRNA transfection, stathmin protein level was reduced by approximately 50% in 
HCT116WTp53 (Figure 2.1B). Stathmin level often returned at later time points (not 
shown), but a second siRNA transfection at 72 hours kept the stathmin level low at day 5 
(time after the first transfection, Figure 2.1B) and up to 7 days after the initial 
transfection (not shown).  These results demonstrate that stathmin can be successfully 
knocked down in HCT116 matched cell lines. 
 
Stathmin is required for cell survival in HCT116 cells lacking p53  
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The HCT116 cell lines were depleted of stathmin using the conditions described above 
and were observed for up to five days post-siRNA transfection to observe the effect of 
stathmin depletion on cell proliferation and death.  First, we followed living cells by 
imaging the same regions of coverslips over a 4 - 5 day time course. For HCT116WTp53 
cells, either expressing stathmin or depleted of stathmin, cell density increased over time, 
reaching near confluency by day 4 - 5 (Figure 2.1C). The same growth characteristics 
were observed for the HCT116p53-/- cell line transfected with a control siRNA. In contrast, 
depletion of stathmin from the HCT116p53-/- line significantly reduced the increase in cell 
number over time (Figure 2.1C). 
 
Following living cells over time suggested that stathmin depletion slowed cell 
proliferation and/or led to cell death only in the HCT116p53-/- cell line. To examine cell 
growth and death more directly, we measured both cell proliferation, by counting the 
number of living cells, and cell death, by counting the percentage of trypan blue positive 
cells over a 5 day time course. HCT116 cells expressing wildtype p53 and depleted of 
stathmin proliferated at a slower rate than cells transfected with a control RNA (solid 
lines, Figure 2.2A).  Although the stathmin depleted HCT116WTp53 cells grew more 
slowly, they remained viable, as measured by trypan blue exclusion (Figure 2.2B). 
Stathmin depletion from HCT116p53-/- cells showed very slow proliferation over a 5 day 
time course (Figure 2.2A, see also Figure 2.1C) and these cells died at a much greater 
rate than HCT116WTp53 cells depleted of stathmin, or either of the HCT116 cell lines 
transfected with a control RNA (Figure 2.2B). There was a high variability in the 
percentage of dead cells in HCT116p53-/- cells depleted of stathmin, as seen by the large 
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standard deviations. At this time we do not know the reason for the inter-experiment 
variability. To confirm that the difference in means was significant, we compared the 
mean percentages of dead cells for control and stathmin-depleted cells within each 
HCT116 cell line at the 5 day time point. The difference in the mean percentage of dead 
cells in HCT116p53-/- control and stathmin-depleted cells was highly significant (p<0.001), 
while the means were not significantly different in HCT116WTp53 cells and HCT116WTp53 
cells depleted of stathmin. Taken together, these results provide strong evidence that 
stathmin is required for cell survival only in cells lacking p53, but the differences in time 
course of stathmin knockdown in cells differing in TP53 genotype complicates analysis. 
 
Restoration of p53 in HeLa cells rescues cells from stathmin-depletion induced 
death 
To further test whether stathmin is required for survival of cells lacking p53, we used 
HeLa cells, which are wildtype for the TP53 gene, but fail to maintain p53 protein level 
because they stably express the human papillomavirus (HPV) E6 protein. The HPV E6 
protein binds p53 and marks it for destruction (Koivusalo et al., 2005). The ability to 
deplete the HPV E6 protein by RNAi (Koivusalo et al., 2005) provides a mechanism to 
restore p53 in HeLa cells, allowing comparison of cells depleted of stathmin in the 
presence and absence of p53. 
 
We first confirmed the results of Koivusalo et al (Koivusalo et al., 2005) that E6 
depletion restores p53 in HeLa cells. Where noted, cells were treated with the DNA-
damaging agent doxorubicin for the 24 hours prior to gel sample preparation to stabilize 
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p53 and enhance its detection. As shown in Figure 2.3A, HeLa cells have a very low 
level of p53, even after doxorubicin treatment. Depletion of E6 by siRNA results in a 
significant increase in p53 level, which is also detectable in cells depleted of both 
stathmin and E6 (Figure 2.3A). 
 
Stathmin was also readily depleted from HeLa cells, as shown in Figure 2.3B. At 72 
hours after siRNA transfection, stathmin was reduced by at least 75%, independent of 
whether cells were also depleted of E6 (p53 restored). Stathmin level was also reduced, 
although to a lesser extent, in cells depleted only of E6. In this latter case, reduced 
stathmin level may reflect the ability of p53 to negatively regulate stathmin expression 
when p53 level is transiently increased (Ahn et al., 1999; Johnsen et al., 2000). 
 
We next examined cell density over time, similar to the experiments performed with 
HCT116 cell lines. Stathmin depletion from HeLa cells reduced the increase in cell 
number over time observed in control-siRNA treated cells (Figure 2.3C). Restoring p53 
(E6 depletion), in the absence or presence of stathmin depletion, resulted in slower cell 
growth compared to control cells, but not nearly as significant an inhibition as that 
observed in stathmin depleted HeLa cells (Figure 2.3C). We then measured both cell 
proliferation (live cell number over time) and the percent dead cells (trypan blue positive) 
for these experimental conditions.  Figure 2.4 shows that stathmin depletion from HeLa 
cells (lacking p53) resulted in both reduced cell proliferation and a large increase in the 
percentage of dead cells.  Comparison of mean percentages of dead cells at day 5 showed 
that stathmin depletion signicantly increased the percentage of dead cells over that 
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measured in control siRNA treated cells (p<0.001). Treatment of cells with siRNA to 
deplete both stathmin and HPV E6 (restoring p53) reversed the effects of stathmin 
depletion alone; cells showed proliferation rates and percentages of dead cells 
comparable to control-treated or HPV E6 siRNA-treated cells.  Finally, we confirmed the 
siRNA results by transfecting cells with a plasmid encoding an shRNA directed against a 
different sequence in the stathmin mRNA (see Methods).  As shown in Figure 2.4 C for 
cells examined 72 hours after transfection, shRNA depletion of stathmin significantly 
increased the percentage of dead cells, compared to cells transfected with a control 
plasmid. Together with the results from HCT116 cell lines, these results provide strong 
evidence that stathmin is required for cell survival only in the absence of p53. 
  
In the above experiments, we used trypan blue exclusion as a simple assay to 
differientiate living and dead cells. It is likely that stathmin depletion results in death by 
apoptosis, as others have demonstrated previously (Alli et al., 2007; Mistry et al., 2005; 
Wang et al., 2009; Zhang et al., 2006). To confirm that cells die via apoptosis we 
examined whether stathmin-depletion induced cell death was inhibited by the capsase 
inhibitor Z-VAD-FMK. As expected, Z-VAD-FMK significantly blocked the death of 
HeLa cells depleted of stathmin (Figure 2.5A,B). Stathmin depleted cells treated with Z-
VAD-FMK also showed cell proliferation rates intermediate between control-treated and 
stathmin-siRNA treated cells. In additional experiments, we found increased levels of 
cleaved poly-ADP ribose polymerase (PARP) in stathmin-depleted HCT116p53-/- cells 
(Figure 2.5C,D), but not in stathmin-depleted HCT116WTp53 cells. These results confirm 
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previous results of others (Alli et al., 2007; Mistry et al., 2005; Wang et al., 2009; Zhang 
et al., 2006) that stathmin depletion initiates apoptotic death in cells lacking p53. 
 
Depletion of p53 and stathmin from non-cancerous cells leads to cell death 
The experiments above, along with previous results of others (Alli et al., 2007; Mistry et 
al., 2005; Zhang et al., 2006), demonstrated that stathmin depletion from cancer cell lines 
results in cell death by apoptosis. We next asked whether non-cancerous cells also require 
stathmin for survival using human foreskin fibroblasts (HFF) as a model non-cancerous 
cell line. To deplete p53 from these cells, we transfected cells with a plasmid for 
expression of an shRNA targeting p53 (Giono and Manfredi, 2007). A successful 
knockdown of both stathmin and p53 was achieved using RNAi and shRNA respectively 
(Figure 2.6A, B).  A 50% knockdown of stathmin was seen as early as day 3 and 
continued to approximately 75% knockdown by day 5. By day 2, p53 showed a 
significant knockdown as well.  Note that the only cells treated with doxorubucin were 
those used to prepare gel samples for p53 detection (as noted in Figure 2.6B).  Depletion 
of stathmin or p53 alone did not inhibit cell proliferation rate and did not increase cell 
death compared to cells transfected with control siRNA or the empty vector used for 
shRNA delivery (Figure 2.6C, D).  Interestingly, however, depleting both stathmin and 
p53 together resulted in significant cell death (p<0.001 at day 5) and a lack of cell 
proliferation (Figure 2.6C, D). These data demonstrate that stathmin is required for cell 
survival in both human cancerous and non-cancerous cell lines lacking p53. 
 
Cells arrest in G2 of the Cell Cycle prior to Apoptosis 
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Both the over-expression of wildtype p53 (Johnsen et al., 2000) and the absence of p53 
(Sur et al., 2009) have been shown to cause cell cycle arrest, at least under some 
experimental conditions. To address whether stathmin depletion leads to a unique cell 
cycle arrest that is dependent upon p53 status, we examined cell cycle distributions in 
HCT116 matched cells depleted of stathmin and HeLa cells depleted of stathmin, HPV 
E6 (restoring p53) or both proteins. Others have previously followed DNA levels and 
identified a G2/M cell cycle arrest after stathmin depletion in cancer-derived cell lines 
(Alli et al., 2007; Mistry et al., 2005), but these studies measured DNA content and 
cannot differentiate between G2 and M phases. Therefore, we used an alternative 
protocol, by staining fixed cells with antibodies to TPX2 (present in the nuclei of S and 
G2 cells and bound to the mitotic spindle microtubules in M phase (Brito and Rieder, 
2006)), Cyclin B (present in the cytoplasm of G2 cells and associated with the mitotic 
spindle until anaphase onset during M phase (Clute and Pines, 1999)), and CDK1 
phosphosphorylated on Tyr15 (Phospho-CDK1(Y15); inhibitory phosphorylation on 
CDK1 present during G2 and removed at entry into mitosis (Borgne and Meijer, 1996)). 
Cells were co-stained with antibodies to tubulin (Figure 2.7 and 2.8), allowing visual 
classification of cells in M phase. Using these staining conditions and counting all cells 
within multiple images, we found that HCT116p53-/- cells depleted of stathmin showed a 
significant (p < 0.05) increase in non-mitotic cells staining positively for TPX2 (Figure 
2.7A, B) or Cyclin B (Figure 2.7C, D) 48 hours post transfection. This result was most 
pronounced in TPX2 stained samples. The mitotic index was approximately equal among 
the two HCT116 lines whether stathmin was depleted or not. 
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We then extended these staining protocols to HeLa cells. Depletion of stathmin from 
HeLa cells also increased the percentage of non-mitotic TPX2 positive cells (Figure 2.8 
A,B) and concomitantly significantly decreased the percentage of cells not recognized as 
TPX2 positive. Untreated HeLa cells, cells treated with a non-targeting siRNA or 
depleted or E6 to restore p53 showed a much smaller percentage of non-mitotic cells 
staining positive for TPX2. As a second marker for cells in G2, we also stained HeLa 
cells with antibodies recognizing phospho-CDK1(Y15), one of the two inhibitory 
phosphorylations holding CDK1 inactive until entry into M phase (Borgne and Meijer, 
1996). Consistent with results from TPX2 staining, HeLa cells depleted of stathmin 
showed a significant increase (p < 0.05) in non-mitotic cells stained positive for phospho-
CDK1(Y15) (Figure 2.8 C,D). Cells depleted of E6 or of E6 and stathmin did not show 
significant changes in the percentage of non-mitotic, phospho-CDK1(Y15) positive cells. 
We confirmed these results by transfecting HeLa cells with a control plasmid or a 
plasmid expressing an shRNA directed against stathmin and again found an increase in 
non-mitotic phospho-CDK1(Y15) positive cells in stathmin-depleted cells (Figure 2.8E). 
From these data, it is evident that stathmin depletion disrupts cell cycle progression, 
leading to an increase in cells positive for G2 markers, but only in the absence of p53. 
Given that others have reported a G2/M block in stathmin depleted cells, based on 
analysis of DNA content, and our results indicate a G2 block, it most likely that cells are 
blocked or delayed in G2, prior to entry into mitosis. Depletion of either stathmin or p53 
alone is not sufficient to delay progression through the cell cycle. 
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Discussion 
 
In the results presented here we demonstrated that stathmin is required for the survival of 
cell lines lacking p53, whether those lines are derived from cancerous or normal tissues. 
Stathmin depletion from HCT116p53-/- and HeLa cells showed significantly reduced 
proliferation rates and an increased percentage of dead cells, while depletion of stathmin 
had little effect on the viability of HCT116WTp53 cells or of HeLa cells expressing p53. 
These observations were not confined to cancer-derived cell lines since normal human 
fibroblasts (HFFs) also required stathmin for proliferation and survival, but only in the 
absence of p53. For both HCT116WTp53 and HPV E6-depleted HeLa cells, stathmin 
depletion slowed cell proliferation somewhat, but did not result in cell death and did not 
impose a cell cycle block. Our results provide direct support for the model proposed by 
Alli et al. (Alli et al., 2007), demonstrating that stathmin is required for survival in cells 
lacking p53.  
  
Several groups have previously reported slowing of cell proliferation and cell death after 
stathmin depletion, but these studies did not address a stathmin requirement for cell 
survival in non-cancerous cells. Zhang et al. (Zhang et al., 2006) developed a method for 
expression of stathmin shRNA driven by the survivin promoter, limiting shRNA 
expression to those cells expressing survivin. Since normal differentiated cells do not 
express survivin, it is unclear whether the survivin promoter would be active, and thus 
expressing stathmin shRNA, in the endothelial cells used as controls. Alli et al. (Alli et 
al., 2007) were unable to deplete stathmin from breast cancer lines expressing p53, 
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making it unclear whether stathmin was required for survival of these cells. Wang et al. 
(Wang et al., 2007) and Mistry et al. (Mistry et al., 2005) examined stathmin depletion in 
cancer cell lines and did not test stathmin's requirement for survival of non-cancerous 
cells. 
 
Our finding that stathmin and p53 depletions from normal human fibroblasts results in 
significantly reduced cell proliferation and increased cell death contrasts with the 
reported viability of mice with both copies of the stathmin and p53 genes knocked out 
(Schubart et al., 1996). It is possible that these mice compensate through increased or 
decreased expression of other proteins allowing normal development and survival in 
these mice. 
 
Stathmin and p53 are required for cell cycle progression 
To address why stathmin is required for cell survival only in cells lacking p53, we 
examined cell cycle distributions in HCT116 cell lines depleted of stathmin and in HeLa 
cells expressing stathmin and p53, either protein alone, or depleted of both proteins. We 
found that cells depleted of both stathmin and p53 show a delay in G2 (based on staining 
for TPX2, cyclin B, phospho-CDK1(Y15) and tubulin) while others have reported a 
G2/M delay in cancer cells depleted of stathmin (Alli et al., 2007; Mistry et al., 2005; 
Wang et al., 2009; Zhang et al., 2006). As discussed above, we think it is likely that cells 
depleted of stathmin and p53 are blocked in G2, prior to entry into mitosis. It is 
interesting that induced expression of p53 both represses stathmin expression and induces 
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a G2/M block (Johnsen et al., 2000). Thus, it is likely that the levels of stathmin and p53, 
rather than simply their presence or absence, contribute to G2/M cell cycle progression.  
 
It is not yet clear why both stathmin and p53 are required for cell cycle progression 
through G2 or for entry into M phase. Stathmin is phosphorylated during mitosis, 
resulting in loss of its microtubule destabilizing activity (Holmfeldt et al., 2006; Larsson 
et al., 1997). Stathmin inactivation is required for proper assembly of the mitotic spindle 
(Holmfeldt et al., 2006; Larsson et al., 1997) and stathmin depletion does not impact 
microtubule formation in the spindle (Ringhoff and Cassimeris, 2009b). Because 
stathmin is normally turned off at entry into mitosis and is not required for spindle 
assembly, it is unlikely that stathmin depletion would prevent entry into mitosis by 
disrupting microtubule assembly and turnover.  
 
Activation of p53, typically in response to DNA damage, primarily induces a G1 block, 
but a G2 block is also possible under some conditions (O'Connell and Cimprich, 2005).  
It is intriguing that many proteins functioning in the G2/M checkpoint, including p53, are 
associated with the centrosome (Wang et al., 2009) and we recently found that stathmin 
regulates microtubule nucleation from the centrosome during interphase (Ringhoff and 
Cassimeris, 2009b). These data suggest that depletion of both stathmin and p53 may 
influence either centrosome function or the function(s) of G2/M checkpoint proteins at 
the centrosome to cause a cell cycle delay during G2. An alternative model is also 
possible, where loss of p53 and stathmin impact separate pathways that together function 
synergistically to slow cell cycle progression. 
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A role for p53, or loss of p53, in regulating G2/M progression was also identified 
recently by comparing transcriptome differences between matched cell lines differing in 
p53 status, including the HCT116 colon cancer cells used here. Cells lacking p53 
upregulated expression of genes functioning in G2/M and were sensitive to treatment 
with a Plk (polo-like kinase) inhibitor (Plk functions in G2 to M progression) (Sur et al., 
2009). In terms of cell proliferation, stathmin depletion acts similarly to Plk inhibition, 
since each treatment slows proliferation of cells lacking p53. Stathmin is one target of 
Plk, but this phosphorylation inhibits stathmin's microtubule regulatory activity (Budde et 
al., 2001). Thus inhibiting Plk will keep stathmin in an active form, which could 
contribute to a G2/M block by preventing proper spindle assembly (Larsson et al., 1997; 
Larsson et al., 1995). It is not clear why stathmin depletion acts similarly to Plk inhibition 
to slow G2/M progression; possibly a balance of stathmin and p53 functions are 
necessary to pass through G2. 
 
Conclusions 
 
Stathmin depletion is required for cell proliferation and survival of those cells lacking 
p53.  Given that p53 is mutated in at least 50% of human cancers, mechanisms to 
specifically target these cells for death hold great promise in treatment of a wide range of 
cancers (Wiman, 2007). Although the cellular mechanism responsible is unknown, our 
data add stathmin depletion to the handful of strategies available to block proliferation of 
those cells lacking a functional p53. Given that nitrosoureas appear to target stathmin and 
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control glioma cell migration (Liang et al., 2008), these compounds may be useful agents 
to induce apoptosis in a mutant p53 background. 
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Figures: 
 
Figure 2.1: Stathmin depletion from HCT116p53WT and HCT116p53-/- cell lines. Matched 
lines of HCT116 cells differing in p53 genotype were treated with siRNA targeting 
stathmin. (A) Stathmin depletion from HCT116p53-/- cells was clearly detectable 24 hrs 
after transfection and stayed low for at least 5 days post transfection. (B) siRNA 
depletion of stathmin from HCT116WTp53 cells. The sample shown at 5 days included a 
second siRNA transfection, 72 hrs after the initial siRNA transfection, which was 
necessary to keep stathmin level low. Samples at 1 and 3 days are from a single siRNA 
transfection. In both (A) and (B), the lysates from non-targeting siRNA treated cells were 
loaded in a dilution series to estimate the extent of depletion by stathmin siRNA. Blots 
were re-probed for actin as an indicator of equal loading between control (100% load) 
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and stathmin-depleted samples. (C) Low magnification phase contrast images of living 
cells acquired at the times given after transfection with control or stathmin siRNA. The 
same field is shown within an experimental condition over 4 - 5 days. HCT116p53-/- cells 
depleted of stathmin remain relatively sparse over the time course while cells grow to 
near confluency in the other experimental conditions. Data shown are representative of 3 
separate experiments. 
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 Figure 2.2:  Stathmin is required for survival of HCT116p53-/- cells.  HCT116 cell lines 
were treated with non-targeting control or stathmin RNAi. At the indicated time points, 
cells were trypsinized, incubated in Trypan Blue to identify dead cells, and numbers of 
living and dead cells counted. Cell proliferation rates (A) and the percentage of dead cells 
(B) represent the means of 3 independent experiments ±SD. 
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Figure 2.3:  Restoring p53 in HeLa cells.  (A) HeLa cells were treated with control or 
siRNA targeting HPV E6 for 72 hrs and exposed to 0.5 µM doxorubicin for the final 24 
hrs to induce DNA damage and stabilize p53, facilitating its detection by immunoblot. In 
control-treated HeLa cells, p53 is present at a very low level, even in the presence of 
doxorubicin. Depletion of HPV E6 restored p53. (B) HeLa cells were treated with siGlo 
control siRNA (or empty vector controls) or siRNAs targeting stathmin, HPV E6 or both 
mRNAs.  Anti-stathmin immunoblot of cell lysates were collected 72 hrs after siRNA 
transfection. Stathmin was depleted by at least 75% after treatment with siRNA targeting 
stathmin or stathmin and HPV E6. Depletion of HPV E6 also caused a reduction in 
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stathmin level, possibly by p53-mediated repression of stathmin expression (Ahn et al., 
1999; Johnsen et al., 2000). For both A and B, blots were re-probed for actin as a marker 
of equal loading between control (100%) and siRNA samples. (C) Low magnification 
phase contrast images of living cells acquired at the times given after transfection with 
control or siRNAs targeting stathmin, HPV E6 or both mRNAs. The same field is shown 
for each experimental condition over 4 - 5 days.  HeLa cells depleted of E6 or stathmin 
and E6 grow slightly slower than control siRNA treated cells, while stathmin depleted 
cells show minimal growth. Data shown are representative of 3 separate experiments. 
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Figure 2.4: Restoring p53 rescues HeLa cells from stathmin-depletion induced death. Cell 
proliferation rates and the percentage of dead cells were measured as described in Figure 
2.2. (A,B) Stathmin depletion slows cell proliferation and increases the percentage of 
dead (trypan blue positive) cells. Depletion of HPV E6 (restoring p53) alone or in 
combination with stathmin depletion does not lead to significant cell death. (C) 
Transfection of cells with an shRNA targeting stathmin resulted in stathmin depletion 
(top) and a significant increase in the percentage of dead cells at 72 hours post-
transfection. Controls were transfected with the negative control plasmid provided by the 
manufacturer. * denotes p<0.05. All data represent the means of 3 independent 
experiments ±SD. 
 
 
 
 
 
 
 
 49 
 
 
Figure 2.5:  Stathmin-depletion induced cell death likely occurs via apoptosis. (A) The 
caspase inhibitor Z-VAD-FMK blocks stathmin-depletion induced cell death in HeLa 
cells. HeLa cells were treated with 10 µm Z-VAD-FMK for 24 hrs prior to transfection 
with either siGlo control siRNA (or empty vector controls) or RNAi against stathmin. 
Plots of cell proliferation rates (A) and the percentage of dead cells (B) represent the 
means of three independent experiments ±SD.  (C) HCT116 matched cell lines were 
transfected with control or stathmin RNAi, fixed 72 hrs later and stained for cleaved 
PARP. The percentage of cells positive for cleaved PARP are plotted. Only HCT116p53-/- 
cells depleted of stathmin show a signficant increase in cells positive for cleaved PARP. 
Data shown are the means ± SD of 3 independent experiments and a total of ~200 cells 
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per treatment. (D) Representative image from HCT116p53-/- cells depleted of stathmin and 
staining positive for cleaved PARP in the nucleus (arrow). Several weakly stained cells 
(counted as negative) are also included. Scale bar = 10 µm. 
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Figure 2.6:  Depleting both p53 and stathmin from normal human fibroblast (HFFs) cells 
leads to cell death.  HFF cells were transfected with TransSilent empty vector, p53 
shRNA plasmid and/or siRNA targeting stathmin as indicated. (A) Anti-stathmin 
immunoblot from cell lysates were isolated 3 days after transfection. A knockdown of 
>75% was observed for both stathmin siRNA alone or when used in combination with 
shRNA against p53. (B) Anti-p53 immunoblot from cell lysates isolated at the times 
indicated. When present, doxorubucin was included for the final 24 hrs of incubation. 
The level of p53 is detectably reduced 1 day after shRNA transfection, but is more 
significantly depleted by 2-3 days after transfection. (C,D) Plots of HFF cell proliferation 
rates (C) and the percentage of dead cells (D) represent the means of 3 independent 
experiments ±SD. 
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Figure 2.7:  Stathmin depletion from HCT116p53-/- cells delays G2 of the cell cycle. 
Matched HCT116 cell lines were treated with either siGlo control siRNA or siRNA 
targeting stathmin mRNAs. (A, B) HCT116 cells were fixed 48 hrs after siRNA 
transfection and stained with antibodies against α-tubulin (green in merged images) and 
TPX2 (red in merged images). TPX2 is present in S/G2 and M phases of the cell cycle 
(Brito and Rieder, 2006). The numbers of TPX2 positive, negative and mitotic cells were 
counted, and the percentage of cells in each group are shown in A.  Images shown in (B) 
are from a representative field of cells transfected with stathmin siRNA. Negative cells 
were identified by their array of interphase microtubules and their lack of TPX2 staining.  
Cells in interphase staining positively for TPX2 were scored as positive.  Mitotic cells 
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were identified by the presence of a mitotic spindle (tubulin staining). Scale bar = 25 µm.  
(C,D) HCT116 cell lines were fixed 48 hrs after siRNA transfections and stained with 
antibodies against α-tubulin (green in merged images) and cyclin B (red in merged 
images). Cytoplasmic cyclin B is a marker of G2 cells (Clute and Pines, 1999). The 
percentage of non-mitotic cyclin B positive and negative cells are shown in (C). Images 
shown in (D) are from representative cells fixed 48 hrs after stathmin siRNA transfection.  
Scale bar = 25 µm. The data represent the means of 3 (C) or 4 (A) independent 
experiments,  each including ~1000 cells ±SD for each treatment group. * denotes p < 
0.05. 
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Figure 2.8:  Stathmin depletion from HeLa cells delays G2 of the cell cycle. HeLa cells 
were transfected with either siGlo control siRNA or siRNA targeting stathmin, HPV E6 
or both mRNAs. (A, B) HeLa cells were fixed and stained with antibodies against α-
tubulin (green in merged images) and TPX2 (red in merged images). Cells were then 
counted as described in Figure 2.7A, and the percent cells in each group are shown in 
Figure 2.8A.  Images shown (B) are from representative cells fixed 48 hrs after siRNA 
transfections. Arrows in the merged image denote several TPX2 positive cells. Scale bar 
= 50 µm. (C,D) HeLa cells were fixed and stained with antibodies against α-tubulin (red 
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in merged images) and phospho-CDK1(Y15) (green in merged images; this inhibitory 
phosphorylation must be removed for entry into M phase). The percentage of non-mitotic 
cells staining positive for phospho-CDK1(Y15) is shown in (C).  Representative images 
from phospho-CDK1(Y15) stained cells are shown in (D). Arrows in the merged image 
denote phospho-CDK1(Y15) positive cells. Scale bar = 50 µm. (E) Depletion of stathmin 
by shRNA also increased the percentage of phospho-CDK1(Y15) positive non-mitotic 
cells at 48 hours after transfection. Each plot represents the mean of 3 independent 
experiments ± SD including ~ 1000 cells per treatment. * denotes p < 0.05. 
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Chapter 3 
 
Increasing Stable Microtubules Leads to G2 Delay in Human Cell Lines 
Lacking p53 
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Introduction: 
 
Stathmin/Oncoprotein 18 is a microtubule (MT) destabilizing protein that is highly over-
expressed in many cancers (Belletti et al., 2008; Bieche et al., 1998; Brattsand, 2000; 
Chen et al., 2003; Friedrich et al., 1995; Kouzu et al., 2006; Melhem et al., 1997; 
Nakashima et al., 2006; Ngo et al., 2007; Nishio et al., 2001; Nylander et al., 1995; Price 
et al., 2000; Yuan et al., 2006).  We and others have recently shown that depleting 
stathmin in certain cancer cells leads to apoptosis (Alli et al., 2007; Carney and 
Cassimeris, 2010; Mistry et al., 2005; Wang et al., 2009; Zhang et al., 2006).  While our 
results confirmed previous observations, we also showed that only when depleting both 
stathmin and p53, a tumor suppressor protein, do cells delay in G2 of the cell cycle and 
activate apoptosis.  What is unknown, however, is whether it is the absence of stathmin’s 
MT destabilizing activity that is causing the cells to delay during G2 and die, or whether 
it is the changes in stathmin’s affects on its other known binding partners that are causing 
these detrimental phenotypes.  Stathmin is best known as a MT destabilizer, but two other 
binding partners, the transcription factor STAT3 and the cyclin-dependent kinase 
inhibitor p27Kip1, could also be responsible for relaying signals downstream of stathmin 
depletion. 
 
Because stathmin is a MT destabilizer, its reduction increases MT polymer (Holmfeldt et 
al., 2006; Howell et al., 1999a; Ringhoff and Cassimeris, 2009b; Sellin et al., 2008), 
inhibits MT dynamic turnover (Howell et al., 1999a; Howell et al., 1999b; Ringhoff and 
Cassimeris, 2009b), and increases MT nucleation from centrosomes (Ringhoff and 
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Cassimeris, 2009b).  P53 also contributes to MT dynamics, although reduced p53 level 
has a relatively minor impact on MT dynamic turnover (Galmarini et al., 2003). To date, 
the effect of stathmin depletion on MT stability has only been measured in cells 
expressing p53 (Belletti et al.; Holmfeldt et al., 2007; Ringhoff and Cassimeris, 2009b) 
and it is not known whether reducing both stathmin and p53 levels will synergize to 
provide a more robust stabilization of the MT cytoskeleton.  If MT stability acts 
downstream of stathmin depletion to slow G2 progression and induce apoptosis, then MT 
stability must be greatest when stathmin is depleted from cells expressing very low levels 
of p53.  
 
Whether MT stability regulates cell cycle progression outside of M phase is 
controversial.  Some have previously suggested that the MT cytoskeleton is necessary for 
interphase cell cycle progression, particularly G2 progression (Balestra and Jimenez, 
2008; Blajeski et al., 2002; Rieder and Cole, 2000), but Uetake and Sluder (Uetake and 
Sluder, 2007) have argued that an interphase MT integrity checkpoint does not exist; 
rather it is the length of the previous mitosis that matters.  It is possible that a MT-
dependent interphase checkpoint is much more robust and detectable only in synergy 
with another factor, such as loss of p53.  Alternatively, it is possible that stathmin level 
controls more than MT stability as discussed next. 
 
Although stathmin’s interactions with tubulin and MTs are well known, they are not the 
only proteins known to interact with stathmin.  P27Kip1, a CDK inhibitor (Baldassarre et 
al., 2005), and STAT3, a transcription factor (Ng et al., 2006), have also been shown to 
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bind to stathmin's C terminal 50 amino acids (Baldassarre et al., 2005; Ng et al., 2006).  
Binding of STAT3 to stathmin has been shown to block stathmin's MT destabilizing 
activity (Ng et al., 2006).  Stathmin depletion does not activate STAT3 (Ng et al., 2006) 
making it unlikely that stathmin depletion signals a cell cycle delay via STAT3 
activation. The CKI, p27kip1 also binds stathmin's C terminus and inhibits its MT 
destabilizing activity.  p27kip1 has recently been shown to cause a G2 delay in addition to 
its known function in G1 (Stacey, 2010).  But, whether stathmin depletion could free 
cytoplasmic p27Kip1, allowing it to enter the nucleus and inhibit cell cycle progression in 
G2 has not been tested, but such a scenario could generate the observed cell cycle delay.  
 
Here we examine whether stathmin depletion relays a cell cycle inhibitory signal through 
stabilization of interphase MTs or through its other binding partners p27Kip1 and STAT3. 
We show that stathmin depletion induces greater MT stability in combination with 
negligible p53 levels.  Additionally, MT depolymerization by incubation in nocodazole is 
sufficient to abrogate the G2 delay and push cells into mitosis.  Finally, we show over-
expression of either GFP-tagged full-length stathmin or stathmin Δ101-149 is sufficient 
to relieve the cell cycle delay. Each of these constructs is active as a MT destabilizer. In 
contrast, signaling via STAT3 or p27Kip1 would be reversed by expression of stathmin 
Δ5-25, and this was not observed. These results indicate that MT stability relays signals 
that can delay the cell cycle in G2. 
 
Methods: 
 
 60 
Cell Culture: 
Cells were grown at 37ºC in a humidified atmosphere of 5% CO2.  HeLa cells were 
grown in either MEM (GIBCO) supplemented with 2.2g/L sodium bicarbonate, 1X 
antibiotic/antimycotic (Sigma), and 10% fetal bovine serum (FBS) (GIBCO-Invitrogen), 
or DMEM (Sigma) supplemented with 1X antibiotic/antimycotic, 1% L-Glutamine 
(Sigma), and 10% FBS.  HCT116p53-/- cells were grown in the same DMEM as HeLa 
cells. 
 
RNA Interference and Transient Transfection: 
RNA interference (RNAi) was achieved using GeneSilencer reagents following the 
manufacturer’s protocol. Cells were grown on 35 mm dishes for 1-2 days before the 
addition of siRNA. Cells were serum starved 30 minutes pre-transfection and 4 hours 
post-transfection to improve transfection efficiency. RNAi oligonucleotides (Dharmacon) 
used included: SMTN1 (Op18-443), 5’- CGUUUGCGAGAGAAGGAUAdtdt-3’, 
(Holmfeldt et al., 2007) STMN1-5’-UTR (only when specified, removes only 
endogenous stathmin mRNA): 5’- CCCAGUUGAUUGUGCAGAAUU-3’and HPV E6 
(18E6-385), 5’-CUAACACUGGGUUAUACAAdtdt-3’ (restores p53 by depleting the 
HPV E6 protein) (Koivusalo et al., 2005).  SiGlo Risc-Free siRNA (Dharmacon) was 
used as a control siRNA sequence for these experiments. 
 
For plasmid transfection, cells were grown similarly to those treated with RNAi except 
that Fugene 6 (Piehl and Cassimeris, 2003; Warren et al., 2006) or X-tremeGene HP was 
used to transfect cells with plasmids.  Cells were transfected with EB1-GFP (Piehl and 
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Cassimeris, 2003) and stathmin-GFP (Ringhoff and Cassimeris, 2009b) as previously 
described (Piehl and Cassimeris, 2003) as well as with two new stathmin truncations (see 
next section). 
 
DNA Constructs of Truncated Stathmin: 
Stathmin truncations lacking either the N-terminus (Δ5-25) or the C-terminus (Δ101-149) 
were constructed using the pEGFP-N1 expression vector.  Full-length stathmin-GFP 
(Ringhoff and Cassimeris, 2009b) was modified using PCR primers to remove the 
desired regions.  Stathmin Δ5-25 was made in a two-step PCR reaction where the 
extreme N-terminal region (1-5) and the 25-149 region were amplified separately and 
then combined in the second reaction (using overhangs designed into the primers) to 
make a full length product where the 5-25 region was removed.  In the first reaction, the 
primers used were: F1 (see below) and R2 to make the N-terminal region and F3 and R4 
to make the 25-149 region.  In the second reaction, the products from the previous 
reactions were combined with primers F1 and R4 to make the full-length truncated 
stathmin product. Stathmin Δ101-149 was made using a single PCR reaction using 
primers F1 and R5 to remove the C-terminus.  Both of these products were then 
digested using BamHI and HindIII and ligated into the pEGFP-N1 expression vector.  
These new constructs were then verified using restriction digestions and sequencing. 
 
Primers: 
 
F1:  5’-GATCCCAAGCTTATGGCTTCT-3’ 
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R2:  5’-TTCTTTTGACCGAGGATCAGAAGAAGCCAT-3’ 
F3:  5’-ATGGCTTCTTCTGATCCTCGGTCAAAAGAA-3’ 
R4:  5’-TCCGGTGGATCCAAGTCAGCTTCAGTCTCGTC-3’ 
R5:  5’-TCCGGTGGATCCAATTTCTCTTCTGCCATTTT-3’ 
 
Indirect immunofluorescence and confocal microscopy: 
Cells were fixed, stained and imaged as described previously (Carney and Cassimeris, 
2010; Piehl and Cassimeris, 2003; Ringhoff and Cassimeris, 2009b).  Primary antibodies 
used were mouse anti-acetylated-tubulin (Clone 6-11B-1; Sigma-Aldrich), rabbit anti-
TPX2 (Garrett et al., 2002) (Gift from Duane Compton, Dartmouth Medical School), 
rabbit anti-phospho-CDK1 (Tyr 15) (Cell Signaling Technology), and rabbit anti-p27 
Kip1 (D69C12; Cell signaling Technology. Goat anti-mouse or rabbit Alexa Fluor 488 or 
563 (Invitrogen) were used as the secondary antibodies in these experiments. Confocal 
microscopy was used to image stained cells as described previously (Carney and 
Cassimeris, 2010; Warren et al., 2006).  Images were acquired using a 40X/1.3NA 
objective.  Image stacks were converted to maximum intensity projections, exported as 
TIFF files and assembled using Photoshop.  For all cell cycle markers, we counted 
interphase cells as stained or unstained, and did not count mitotic cells on most 
experiments. 
 
Relative intensity was measured using MetaMorph software (Universal Imaging, 
Downington, PA).  Cells were fixed and stained for α-tubulin.  Images were taken of 
microtubules at the cell periphery and then compared between the treatments. 
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Live Cell Imaging of EB1-GFP: 
Confocal microscopy was used to image live cells as described previously (Warren et al., 
2006).  Using EB1-GFP (Piehl and Cassimeris, 2003; Warren et al., 2006) to measure 
nucleation rates, images were taken every 2 seconds for up to 2 minutes.  EB1-GFP 
comets were counted as they emerged from the centrosome and used as a measure of 
nucleation rate. 
 
Protein Isolation and Western Blotting: 
Soluble cell extracts were prepared for SDS-polyacrylamide gel electrophoresis as 
described previously (Carney and Cassimeris, 2010).  Protein concentrations were 
measured by Bradford assay (Bradford, 1976). Membranes were probed and imaged as 
previously described (Carney and Cassimeris, 2010) using primary antibodies rabbit anti-
stathmin (Sigma-Aldrich or Cell Signaling Technology), mouse anti-acetylated-tubulin 
(Clone 6-11B-1; Sigma-Aldrich), or goat anti-GAPDH (Abcam) followed by goat anti-
mouse or rabbit horseradish peroxidase-linked IgG (Sigma-Aldrich) or rabbit anti-goat 
IgG HRP (Abcam). 
 
Statistics: 
Statistical analysis of cell counts and intensity readings, including those determined after 
immunofluorescent staining (above), were performed using unpaired t-tests in Microsoft 
Excel or GraphPad Software (www.graphpad.com/quickcalcs/ttest1.cfm). 
 
 64 
Results: 
 
Microtubule stability and nucleation increase following stathmin depletion only 
when p53 is lacking. 
Stathmin depletion from cells lacking p53 results in a G2 cell cycle delay (Carney and 
Cassimeris, 2010; Caruso, V. and Cassimeris, unpublished), and restoring p53 is 
sufficient to abrogate this delay (Carney and Cassimeris, 2010). If stathmin depletion is 
relaying a signal via increased MT stability, we predict that interphase MT stability will 
be greatest when both stathmin and p53 are reduced. We tested this prediction using 
HeLa cells because we previously demonstrated that we could lower stathmn by siRNA 
and restore p53 by depleting the HPV E6 protein, which normally targets p53 for 
destruction in these cells (Carney and Cassimeris, 2010). We examined two 
characteristics of MTs that are known to change when stathmin is depleted:  the levels of 
acetylated α-tubulin, which serves as a marker of stable MTs (Belletti et al., 2008; 
Cambray-Deakin and Burgoyne, 1987; Perdiz et al.; Schulze et al., 1987), and 
centrosomal MT nucleation rate, which is dependent on stathmin level (Ringhoff and 
Cassimeris, 2009b). 
 
In order to look for a change in the amount of stable MTs, we used the presence of 
acetylated tubulin as a marker.  HeLa cells were depleted of either stathmin, HPV E6 
(restoring p53), or both stathmin and HPV E6 and then allowed to grow for 72 hours post 
transfection (Carney and Cassimeris, 2010).  Western blotting showed a significant rise in 
acetylated tubulin when stathmin is depleted alone, but not when p53 is restored (Figure 
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3.1A).  When both stathmin and E6 are depleted, no significant change in acetylated 
tubulin level is observed (Figure 3.1A).  Using confocal microscopy, we observe the 
same effect (Figure 3.1B).  Only when stathmin is depleted from cells lacking p53 does 
the presence of acetylated tubulin increase.  Restoring p53 reverses the effect of stathmin 
depletion on acetylated tubulin. We also observed an increase in the presence of 
acetylated tubulin in HCT116p53-/- cells when stathmin was depleted; while HCT116 cells 
depleted of stathmin showed no change compared to control treated cells (Figure 3.8). 
 
Experiments in mouse embryo fibroblasts derived from wild-type and stathmin knockout 
mice showed that stathmin knockout significantly increased the rate of MT nucleation 
from centrosomes with less dramatic effects on MT dynamic instability (Ringhoff and 
Cassimeris, 2009b).  Therefore, we used MT nucleation as a measure of MT stability in 
HeLa cells depleted of stathmin to determine if there was a change in MT dynamics.  To 
measure centrosomal MT nucleation rate we observed live cells expressing EB1-GFP 
(Piehl et al., 2004).  Cells were depleted of stathmin, HPV E6, or both proteins and then 
allowed to grow for 24 hours.  EB1-GFP plasmid was then transfected into the cells, 
which then continued to grow for an additional 48 hours.  Using live cell imaging, MT 
nucleation rate was determined by observing the number of EB1 comets emerging from 
the centrosome per minute.  Depletion of stathmin increased nucleation rate significantly 
compared to siGlo treated controls, while restoring p53 had no effect on MT nucleation 
rate compared to control levels (Figure 3.1C).  Depletion of both stathmin and HPV E6 
(restoring p53) caused nucleation rate to return to control levels.  Taken together, these 
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data provide strong evidence that there is indeed an increase in MT stability when 
stathmin is depleted, but only in combination with negligible levels of p53.  
 
Removing MTs with nocodazole allows p53 null cells to escape the G2 block induced 
by stathmin depletion. 
The results shown above demonstrated that MT stability is increased significantly when 
both stathmin and p53 levels are very low, but do not address whether stathmin depletion 
induces a G2 delay via increased MT stability.  To establish whether MT stability is 
necessary for the G2 delay in stathmin-depleted cells, we asked whether nocodazole-
induced MT depolymerization could eliminate the cell cycle delay.  Cells were grown for 
40-48 hours post transfection with siRNA directed against stathmin and then incubated in 
33µM nocodazole for 3 - 5 hours prior to fixation.  After 3 - 5 hours of exposure to 
nocodazole, the MT network was depolymerized to near completion (Figure 3.9).  Cells 
were also stained with several markers to identify cells in G2.  Although MTs were no 
longer present, interphase and mitotic cells were still easily differentiated by cell 
morphology (not shown). 
 
Consistent with our previous results (Carney and Cassimeris, 2010), HeLa cells depleted 
of stathmin showed about a 2 fold increase in the percent of interphase cells staining 
positively for TPX2, a protein expressed in the nucleus in late S and G2 (Brito and 
Rieder, 2006), when compared to control treated cells (Figure 3.2A).  The percent of 
TPX2 positive cells returned to control levels when cells were also treated with 
nocodazole (Figure 3.2A).  Using phospho-CDK1(Y15) (Borgne and Meijer, 1996), as a 
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second marker of G2 cells, we saw a similar effect, where nocodazole treatment reduced 
the percent of stathmin-depleted cells staining positive for this marker (Figure 3.2B).  
Although the percent of positively stained cells was not statistically significant between 
stathmin depleted cells treated with nocodozale or not, the results showed the same 
pattern as TPX2 localizations, where nocodazole reduces the percent of cells in G2.  Cells 
that normally delay in G2 following stathmin depletion should proceed into mitosis after 
MT disruption by the addition of nocodazole. The previous counts considered only 
interphase cells. Therefore, we also measured the mitotic index and found as expected, 
nocodazole treatment also increased the mitotic index (Figure 3.10). 
 
We repeated this experimental protocol, using HCT116p53-/- cells, as a second model 
system in which to test whether the removal of MTs was sufficient to bypass a stathmin-
depletion induced G2 delay.  Using TPX2 as a marker and following the same procedure 
as above, we saw a statistically significant increase in the percent of TPX2 positive 
interphase cells after stathmin depletion.  This is consist with our previous results using 
this marker in HCT116p53-/- cells (Carney and Cassimeris, 2010).  Following the addition 
of nocodazole, stathmin depleted cells staining positive for TPX2 returned to a 
percentage of the total interphase population equivalent to controls (Figure 3.2C). Taken 
together, these data demonstrate that MT depolymerization is sufficient to abrogate a G2 
cell cycle delay caused by stathmin depletion. 
 
Over-expression of truncated stathmin proteins, after the depletion of endogenous 
stathmin, can change whether the cells delay in G2 of the cell cycle. 
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The above results support a model where increased MT stability relays a signal that 
delays cell cycle progression during G2. To confirm this conclusion, and to test whether 
either STAT3 or p27Kip1 could contribute to signals generated by stathmin depletion, we 
examined whether expression of stathmin, or stathmin truncations, could alleviate the G2 
delay.  Plasmids for expression of GFP-tagged stathmin truncations were designed to 
delete either the N- (Δ5-25) or C- (Δ101-149) terminus (Figure 3.3A).  The Δ5-25 
truncation should not depolymerize MTs (Larsson et al., 1999), but should bind both 
STAT3 and p27Kip1(Baldassarre et al., 2005; Ng et al., 2006). The Δ101-149 truncation 
should depolymerize MTs (Larsson et al., 1999) but lacks the region necessary to bind 
STAT3 or p27Kip1. Truncations were expressed in cells and each was expressed at the 
correct molecular weight for a fusion protein with GFP (Figure 3.3B). 
 
The microtubule cytoskeleton was then examined in cells over-expressing these 
truncations as well as full-length stathmin fused to GFP.  Over-expression of either full 
length-stathmin or stathmin Δ101-149 caused a decrease in the MTs and this was most 
easily seen at the cell periphery.  Image intensity measurements confirmed the decrease 
in MT polymer in these cells (Figure 3.4B).  Expression of stathmin Δ5-25 did not 
change the MT network when compared to control treated cells (Figure 3.4). As expected 
based on previous results (Holmfeldt et al., 2006; Howell et al., 1999a; Ringhoff and 
Cassimeris, 2009b; Sellin et al., 2008), stathmin depletion increased the amount of MT 
polymer, as measured at the cell periphery (Fig 3.4A). 
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To knockdown endogenous stathmin mRNA while allowing expression of GFP-tagged 
proteins, an siRNA against the 5-UTR of endogenous stathmin was used. This siRNA 
was as effective as those targeting the coding sequence in reducing stathmin level (Figure 
3.3B) and was also as effective in causing a G2 cell cycle delay (Figure 3.5).  Following 
endogenous stathmin depletion, cells were transfected with plasmids for expression of 
GFP or GFP- fused to stathmin, stathmin Δ5-25, or stathmin Δ101-149.  This method 
allowed depletion of endogenous stathmin, while all three stathmin versions were 
expressed (Figure 3.3B).  These cells were allowed to grow for 48 hours after transfection 
before being fixed and stained. 
 
Expression of GFP-tagged stathmin truncations were then used to test whether either 
protein could rescue the G2 delay caused by stathmin depletion.  If MT stability is the 
critical signal relay downstream of stathmin depletion, then over-expression of stathmin-
GFP or stathmin Δ101-149 should abrogate the delay, but expression of the stathmin Δ5-
25 truncation should not change the delay. 
 
Cells expressing stathmin-GFP and depleted of the endogenous protein, showed a 
reversal of the G2 delay and had a percentage of cells in G2 similar to control levels.  
Stathmin Δ5-25 expression did not change the percent of cells delayed in G2.  Similar to 
stathmin depletion alone, this treatment had about a two-fold increase in the percent of 
TPX2 positive interphase cells when compared to controls.  Over-expression of stathmin 
Δ101-149, on the other hand, resulted in a percentage of TPX2 positive interphase cells 
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similar to control cells and thus successfully rescued the cell cycle delay observed when 
stathmin is depleted (Figure 3.5A). 
 
We observed a similar effect after these transfections when phospho-CDK1 was used as a 
marker of cells in G2.  Cells that normally delay in G2 following stathmin depletion 
escaped the delay only when MTs were altered by the expression of either WT-stathmin 
or stathmin Δ101-149.  As previously shown, when stathmin Δ5-25 is reintroduced, the 
percentage of interphase cells positive for phosphorylated CDK1 remains at an elevated 
level compared to control treated cells (Figure 3.5B).  These results suggest that cells can 
only escape the G2 cell cycle delay when the MT network is depolymerized (using full-
length stathmin or stathmin Δ101-149) following stathmin depletion.   
 
Expression of stathmin truncations also allows us to establish what, if any, roles p27kip1 
and STAT3 might play in the cell cycle arrest that is observed following stathmin 
depletion.  Both p27kip1 and STAT3 bind to the C-terminus of stathmin (Baldassarre et 
al., 2005; Gao and Bromberg, 2006; Ng et al., 2006). If stathmin binding contributes to 
their localization in the cytoplasm, where they are inactive, then expression of full-length 
stathmin or stathmin Δ5-25 could bind and sequester either of these two proteins in the 
cytoplasm, preventing their nuclear entry.  On the other hand, stathmin Δ101-149 would 
not be able to bind either p27kip1 or STAT3 and they would be free to move to the nucleus 
and possibly delay the cell cycle.  Figure 3.5 shows that this model is highly unlikely 
because our observations are directly opposite of what this model would propose. 
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Specifically, it is the expression of the Δ101-149 truncation that rescues the stathmin-
depletion induced cell cycle delay and not the expression of the Δ5-25 truncation. 
 
P27kip1 localization does not change when stathmin is depleted. 
As described above, stathmin has two identified binding partners in addition to tubulin 
that could contribute to a G2 cell cycle delay. Previous data from Ng et al (2006) showed 
that STAT3 is not activated following stathmin depletion and our results from expression 
of stathmin truncations further confirmed that stathmin depletion is not relaying signals 
via STAT3 activation.  The expression of stathmin truncations and the rescue of a G2 cell 
cycle delay by the Δ101-149 truncation also did not support involvement of p27Kip1. To 
further exclude p27kip1 involvement, we tested whether stathmin depletion activated 
p27Kip1, as measured by p27 localization to the nucleus.  HeLa cells were depleted of 
stathmin for 48 hours after which they were fixed and stained for p27kip1.  The protein 
showed no increase in the percent of interphase cells scored positive for nuclear p27Kip1 
after stathmin depletion (Figure 3.6).  As a positive control, MG132 (a proteosome 
inhibitor) was used to stabilize p27kip1 and this stabilization significantly increased the 
percentage of interphase cells scored positive for nuclear p27Kip1.  Therefore, these results 
do not support a role for p27Kip1 in mediating the G2 delay observed after stathmin 
depletion. 
 
Discussion: 
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We explored the signal downstream of stathmin depletion sufficient to cause a G2 cell 
cycle delay and found that increased MT stability is the likely source of delayed cell 
cycle progression.  In stathmin-depleted cells, MT depolymerization by nocodazole 
treatment was sufficient to abrogate the G2 cell cycle delay. These data indicate that MT 
stability acts downstream of stathmin depletion to cause the delay since depolymerizing 
MTs allows cell to escape into mitosis. Additional support for MT stability acting 
downstream of stathmin depletion comes from experiments to rescue the G2 delay by 
expression of stathmin truncations. Expression of GFP-tagged full-length stathmin or 
stathmin Δ101-149, after depletion of endogenous stathmin, both decreased MTs and 
reduced the population of cells in G2 to that measured in cells transfected with control 
siRNA.  Over-expressing stathmin Δ5-25, which has no effect on MTs, however, did not 
affect the percentage of cells in G2.  Taken together, these experiments also indicate that 
neither p27kip1 nor STAT3, alternative binding partners of stathmin, is responsible for 
relaying a cell cycle delay downstream of stathmin depletion, since they bind to 
stathmin’s C-terminus and over-expressing stathmin Δ101-149 still rescues the delay.  
Instead, our results provide strong evidence that excess MT stability can delay the cell 
cycle during interphase.  Based on these results, it is evident that a stathmin-dependent 
change in the MT network leads to a cell cycle delay and not an alternative function of 
stathmin's via its other binding partners, STAT3 and p27kip1. 
 
The MT phenotypes, observed after lowering stathmin level, like increased nucleation 
rate and higher polymer level, have been shown in cells expressing p53 (Belletti et al.; 
Holmfeldt et al., 2007; Ringhoff and Cassimeris, 2009b), so why do we only see these 
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effects on MTs when both p53 and stathmin are depleted?  Although we do observe slight 
increases in both nucleation rate and stable MTs when stathmin is depleted in p53-
positive cells, they are not significant and are much lower then previously published 
results.  The differences we observe here may be due to the fact that we are transiently 
restoring p53 thereby altering its level in the cell compared to other experiments where 
the cells constitutively express wild-type p53.  Stathmin depletion changes the expression 
of many genes (Ringhoff and Cassimeris, 2009a), and these changes could differ in a 
p53-dependent fashion.  These differences in gene expression may complicate 
comparisons.  Taken together, these may account for the disparity we observe here. 
 
While the depletion of stathmin leading to a G2 delay might seem logical because 
increased MT stability reduces the ability of a cell to form a spindle, this is not the case 
when cells are exposed to paclitaxel (Taxol).  Although treatment with taxol has been 
shown to significantly increase mitotic duration due to a mitotic block (Gascoigne and 
Taylor, 2009), it does not change interphase duration (Uetake and Sluder, 2007).  This 
differs greatly from what we see when stathmin is depleted, suggesting that the two cells 
differ in how they enter mitosis.  In taxol treated cells, MTs reorganized uniquely leading 
to the formation of a bizarre state where nucleation sites accumulate at the cell periphery 
leading to improper spindle formation (Hornick et al., 2008).  Since stathmin is turned off 
in mitosis due to phosphorylation of the protein (Larsson et al., 1997; Larsson et al., 
1995), stathmin-depleted cells may not develop the odd phenotype associated with taxol 
treatment and delay in G2 until a proper spindle can form.  Nguyen et al (1997) also 
observed an increase in interphase duration and a G2 delay when MAP4 (a MT stabilizer) 
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is over-expressed, further supporting the idea that stathmin depletion acts outside of 
mitosis and generates a more natural state of stability, since stathmin and MAP4 act 
antagonistically and therefore differently then taxol. 
 
However, as we stated earlier, MT stability’s role in regulating cell cycle progression 
outside of M phase has been controversial. Rieder and others suggested that the MT 
cytoskeleton is necessary for cell cycle progression through G2 in numerous cell types 
(Balestra and Jimenez, 2008; Blajeski et al., 2002; Rieder and Cole, 2000).  They suggest 
the presence of “MT integrity checkpoint” which must be met before the cell can escape 
G2 and enter mitosis. Uetake and Sluder (2007) disagreed, instead suggesting that it is the 
length of the previous mitosis that matters.  In their experiments, Uetake and Sluder used 
taxol to stabilize MTs and showed that there is no change in the interphase duration, 
however the unique MT phenotype resulting from taxol exposure could, however, be 
responsible for the observed effects.  Unpublished data from our lab shows that depletion 
of stathmin has no effect on mitotic duration when compared to controls (Caruso, V. and 
Cassimeris, unpublished), indicating that our observed G2 delay is not the result of a 
previous slowed mitosis.  Our results support the idea of a “MT integrity sensor” which 
monitors the state of the MT network before the cell can enter mitosis or slows the 
kinetics of mitotic entry during the transition form G2 to M.   
 
The question still remains as to why the G2 delay only occurs when both stathmin and 
p53 are absent. Although loss of p53 only has a minor effect on MT dynamic turnover 
(Galmarini et al., 2003), p53 has been shown to localize to the centrosome (Tarapore and 
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Fukasawa, 2002).  P53’s localization to the centrosome turns out to be important in 
amplification of the centrosome itself (Fukasawa, 2008; Tarapore and Fukasawa, 2002).  
When p53 is absent, cells show an increase in both centrosome number and the rate of 
chromosome mis-segregation (Tarapore and Fukasawa, 2002).  This change in 
centrosome structure could also account for the changes in MT dynamics observed by 
Galmarini et al (2003).  If this is the case, any additional disruption to the MT network 
when p53 is absent, such as stathmin depletion, may intensify changes to MT dynamics 
including the stability of MTs thereby signaling the cell to stall the cell cycle.  
Previously, Ringhoff and Cassimeris (2009b) showed an increased nucleation at the 
centrosome in MEF cells where stathmin has been knocked out and for HeLa cells where 
stathmin had been depleted, we found this increased nucleation rate only when combined 
with negligible levels of p53.  The ability of p53 and stathmin to impact centrosome 
structure or function may place centrosomes as the critical signal integrator.  The 
increased MT stability and nucleation rate could also lead to both difficulties breaking 
down the MT array before the cell enters mitosis, as well as disruptions or alterations to 
signal transduction via MTs (discussed below). 
 
Microtubule stability transduces signals to delay cells in G2. 
Before the cell can enter mitosis, the interphase MT array must break down and 
reorganize to form the mitotic spindle (Figure 3.7A).  During prophase, centrosomes 
separate and astral arrays form with long MTs, as polymer level remains constant.  A 
steep drop in polymer level occurs near the time of nuclear envelope breakdown despite a 
dramatic increase in nucleation (Zhai et al., 1996).  This shift occurs rapidly and is 
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accomplished by disassembly of individual MTs from a change in dynamic instability 
favoring disassembly and by shuttling of MT bundles by cytoplasmic dynein toward the 
nuclear envelope (Rusan et al., 2002).  Increased stability of MTs at this point would 
likely hinder the reorganization process.  We hypothesize that delayed mitotic entry 
results from disrupted reorganization of the interphase MT array (Figure 3.7B), and may 
act as a physical signal to delay the cell cycle.  However, increased stabilization of MTs 
may also affect other more conventional signaling pathways as well. 
 
Microtubules’ acting to relay signals is not a novel idea, but is an area that has not been 
well studied.  MTs have been proposed to be involved in not only signaling to control the 
cell cycle and differentiation (Sobel, 1991), but they are also believed to be important in 
many other signal cascades (Gundersen and Cook, 1999).  Therefore, changes to the MT 
network can drastically alter these signals affecting not only the cell cycle, but many 
other cell functions, as well.  MTs are also known to sequester many proteins, including 
GEF-H1, an activator of RhoA (Chang et al., 2008), as well as to act as docks for other 
signaling scaffolds, such as those in MAPK pathway (Gundersen and Cook, 1999) and 
the glycolytic pathway (Durrieu et al., 1987; Knull and Walsh, 1992; Lehotzky et al., 
1993; Vertessy et al., 1997).  When stathmin is depleted and the amount of stable MTs 
increases, this changes the way such scaffolds function, by changing not only scaffolding 
but delivery, sequestration, and the release of many proteins that both directly and 
indirectly interact with the MTs (Gundersen and Cook, 1999) (Figure 3.7C). 
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The glycolytic pathway, for example, can also bring the absence of p53 back into the 
picture, since this protein has been shown to have some control over metabolic regulation 
(Maddocks and Vousden).  When p53 is lacking the amount of glycolysis increases, 
promoting an amplification in the Warburg effect (high rate of aerobic glycolysis 
characteristic of cancer cells).  The ability of the cell to adapt metabolically also 
decreases and as a result cells become more sensitive to metabolic stress (Maddocks and 
Vousden).  Changes in MT stability, following stathmin depletion in p53 null cells, may 
provide additional stress, thereby activating stress pathways, leading to a delay in the cell 
cycle and apoptosis.   
 
Although we are not sure of the exact downstream mechanism, it is clear that MT 
stability plays an important role in G2 progression and mitotic entry.  It is also evident 
that the role of MTs is regulated in an unknown p53-dependent process in which it is 
likely that p53 suppresses the amount of stable MTs.  If MT stability increases and p53 is 
no longer present to prevent it, the cell proceeds to delay in the cell cycle. 
 
Conclusion: 
 
Stathmin depletion in p53 null cells leads to a significant increase in MT stability.  This 
stability activates an as yet unknown signal pathway that leads to a cell cycle delay and 
although not studied here most likely apoptosis as well.  This synergistic affect on the cell 
cycle when both p53 and stathmin are depleted could prove promising in the treatment on 
a wide array of cancers. 
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Figures: 
 
Figure 3.1:  Stathmin depletion from HeLa cells increases MT stability only when p53 is 
absent.  HeLa cells were transfected with siGlo control siRNA or siRNA targeting 
stathmin, HPV E6, or both mRNAs.  (A) Cells were fixed 72 hrs after transfection and 
then stained with antibodies against acetylated tubulin. Representative images of each 
treatment are presented here.  (B) Anti- acetylated tubulin immunoblot from cell lysates 
isolated 72 hrs after transfection.  (C) MT nucleation rates were determined by 
transfecting HeLa cells with EB1-GFP 24 hrs after siRNA treatment.  Live cell imaging 
at the centrosome was performed 48 hrs after EB1-GFP transfection.  Images were used 
to count the number EB1 comets emerging from the centrosome per minute.  Box plot 
represents the mean of 3 independent experiments. **denotes p<0.0001, °denotes 
outliers. 
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Figure 3.2:  Depolymerizing MTs with nocodazole allows cells to escape the G2 delay in 
both HeLa and HCT116p53-/- cells.  Cells were transfected with either siGlo control 
siRNA or siRNA targeting stathmin mRNA.  40-48 hrs after transfection, cells were 
treated with DMSO, as a control, or 33µM nocodazole for 3-5 hrs before fixation and 
staining.  (A) HeLa cells were stained with antibodies against α-tubulin and TPX2.  The 
numbers of TPX2 positive and negative cells were counted, and the percentage of 
interphase cells staining positive are shown in A.   (B) HeLa cells were stained with 
antibodies against α-tubulin and phospho-CDK1(Y15).  The numbers of phospho-
CDK1(Y15) positive and negative cells were counted, and the percentage of interphase 
cells staining positive are shown in B.  (C) HCT116p53-/- cells were stained with 
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antibodies against α-tubulin and TPX2.  The numbers of TPX2 positive and negative 
cells were counted, and the percentage of interphase cells staining positive are shown in 
C. Each plot represents the mean of 3 independent experiments ± SD. *denotes p<0.01 
and **denotes p<0.001. 
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Figure 3.3:  Stathmin truncations can be expressed in HeLa cells in the presence of 
siRNA against the 5’UTR region of stathmin mRNA.  (A) Represents the three stathmin-
GFP fusion proteins designed for these experiments.  (B) Cells where treated with either 
siGLO control siRNA or siRNA against the 5’UTR region of stathmin mRNA, to deplete 
only the endogenous stathmin.  Ten minutes after siRNA treatment cells were transfected 
with either GFP or one of the three stathmin-GFP fusion proteins.  Anti-stathmin 
immunoblots from cell lysates were isolated 72 hrs after the second round of transfection.  
In order to get a successful blot, two stathmin antibodies were used separately because 
the Sigma stathmin antibody recognizes the extreme C-terminus, and will not recognize 
all the truncations, while the Cell Signaling stathmin antibody (binds around S38) failed 
to recognize endogenous stathmin, but was able to recognize all the truncations. 
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Figure 3.4:  Stathmin truncations change MT polymer at the cell periphery.  Cells were 
transfected with GFP, one of three stathmin GFP fusion proteins, or siRNA against 
stathmin mRNA.  (A) Cells were fixed 72 hrs after transfection and then stained with 
antibodies against α-tubulin.  GFP expressing cells were imaged at the cell periphery in 
order to discern differences in MT polymer.  Representative images of two cells 
transfected with each construct are shown in A.  (B) Relative intensity data was collected 
from all images using Metamorph software.  Each plot represents the mean of 2 
independent experiments ± SD, consisting of  >10 cells for each treatment. ** denotes 
p<0.005. 
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Figure 3.5:  Over-expression of truncated stathmin can rescue the cells from a G2 delay 
following depletion of endogenous stathmin. Cells were transfected with either siGLO 
control siRNA or siRNA against the 5’UTR region of stathmin mRNA.  Ten minutes 
after siRNA treatment cells were transfected with either GFP or one of the three 
stathmin-GFP fusion proteins before fixation and staining.  (A) HeLa cells were stained 
with antibodies against α-tubulin and TPX2.  The numbers of TPX2 positive and 
negative cells were counted, and the percentage of interphase cells staining positive are 
shown in A.   (B) HeLa cells were stained with antibodies against α-tubulin and phospho-
CDK1(Y15).  The numbers of phospho-CDK1(Y15) positive and negative cells were 
counted, and the percentage of interphase cells staining positive are shown in B.  Each 
plot represents the mean of 3 (A) or 4 (B) independent experiments ± SD. *denotes 
p<0.05 and +denotes p<0.055. 
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Figure 3.6:  Stathmin depletion does not increase p27Kip1 localization in nucleus.  HeLa 
cells were transfected with either siGlo control siRNA or siRNA targeting stathmin 
mRNAs. 40-48 hrs after transfection, cells were fixed and stained.  As a positive control, 
cells were treated with MG132 (5µM), a proteosome inhibitor, for 5-6 hrs before fixation.  
Cells were stained with antibodies against α-tubulin and p27Kip1.  (A) The numbers of 
p27Kip1 positive and negative cells were counted, and the percentage of interphase cells 
staining positive are shown in A.  (B) Images shown are from a representative field of 
cells transfected with stathmin siRNA or the drug MG132.  The plot above represents one 
of two independent experiments, representing >200 cells per condition. 
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Figure 3.7:  Models for how stathmin depletion in p53 null cells leads to a G2 delay.  (A) 
Under normal conditions, the cell can depolymerize its MTs and form a proper spindle 
allowing entry into mitosis.  However, stathmin depletion in p53 null cells leads to a G2 
delay in a yet unknown mechanism.  (B) After stathmin depletion, cells could have an 
inability to properly depolymerize their MT arrays and successfully progress into mitosis.  
(C) Depleting stathmin could, on the other hand, cause a disruption of cellular signaling 
(in this case a change in the ratio of free/bound protein). 
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Figure 3.8: Stathmin depletion from HCT116wt-p53 and HCT116p53-/- cells increases MT 
stability only when p53 is absent.  HCT116 cells were transfected with siGlo control 
siRNA or siRNA targeting stathmin mRNA.  Cells were fixed 72 hrs after transfection 
and then stained with antibodies against acetylated tubulin.  Representative images of 
each treatment are presented here. 
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Figure 3.9:  Nocodazole depolymerizes MTs in HeLa cells. Cells were treated with either 
DMSO or 33µM nocodazole for 3-5 hrs before fixation and staining. HeLa cells were 
stained with antibodies against α-tubulin and TPX2.  This treatment is sufficient to 
depolymerize MTs in these cells.  These are representative images of a field of cells for 
each treatment. 
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Figure 3.10:  Mitotic index increases when cells are treated with nocodazole independent 
of stathmin depletion. Cells were transfected with either siGlo control siRNA or siRNA 
targeting stathmin mRNA.  40-48 hrs after transfection, cells were treated with DMSO or 
33µM nocodazole for 3-5 hrs before fixation and staining.  (A) HeLa cells were stained 
with propidium iodide (PI) and mitotic index was determined. 
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Conclusions 
 
Stathmin has been known to play key roles in MT dynamics.  Stathmin’s functions in 
regulating dynamic instability (Holmfeldt et al., 2002; Howell et al., 1999a), tubulin 
sequestering (Howell et al., 1999b), and MT polymer content (Holmfeldt et al., 2007) are 
well established.  Stathmin has also been shown to be highly over-expressed in many 
cancers (Belletti et al., 2008; Bieche et al., 1998; Brattsand, 2000; Chen et al., 2003; 
Friedrich et al., 1995; Kouzu et al., 2006; Melhem et al., 1997; Mistry et al., 2005; Ngo et 
al., 2007; Nishio et al., 2001; Nylander et al., 1995; Price et al., 2000; Yuan et al., 2006) 
which constitute some of the most malignant and hardest to treat cancers.  Only recently 
has stathmin been shown to have a role in cell cycle delay and apoptosis (Alli et al., 
2007; Mistry et al., 2005; Wang et al., 2009; Zhang et al., 2006).  However, although Alli 
et al proposed the involvement of p53 in these pathways, it had not been tested directly.  
Here I tested Alli et al’s hypothesis directly (chapter 2) and determined how such a 
pathway might function (chapter 3). 
 
In chapter 2, I showed that only cells lacking both p53 and stathmin activate a G2 cell 
cycle delay and die via apoptosis, similar to what Alli et al (2007) hypothesized.  While 
the knockdown of either protein alone showed a slight slowing of the cell cycle, this type 
of depletion does not lead to a delay or apoptosis (Carney and Cassimeris, 2010).  
Restoring p53 to cells that normally lack a functional copy of the protein rescued both the 
delay and the apoptosis that is observed in their p53 lacking counterparts (Carney and 
Cassimeris, 2010).  This is the case for both cancer cell lines tested (HeLa and HCT116), 
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as well as a non-cancerous primary cell line (HFF).  Stathmin depletion could prove to be 
very effective as a means of selectively targeting for death only cells that have an absent 
or nonfunctional p53.  As a siRNA-based therapy, depletion of stathmin would allow for 
treatment of cancers lacking p53 that normally have a poor prognosis and are relatively 
hard to treat (Wallace-Brodeur and Lowe, 1999).  While depletion of stathmin would kill 
p53 null cells, it would be able to leave the surrounding cells relatively unaffected since 
depletion of stathmin from healthy cells not only fails to activate apoptosis (Carney and 
Cassimeris, 2010), but those same healthy cells can still grow and proliferate normally 
without the presence of stathmin (Schubart et al., 1996).  However, siRNA-based 
treatments are thus far unsuccessful or not optimal in animal models (Higuchi et al., 
2010; Kim et al., 2009).  Identifying the pathway where stathmin knockdown acts 
therefore could lead to other potential targets where it may be easier to design treatments 
until siRNA technology improves.  Which begs the question, what about stathmin’s 
depletion in these p53 null cells is leading to both the G2 delay and apoptosis? 
 
Chapter 3 answers how stathmin depletion leads to a cell cycle delay.  In the third chapter 
of this dissertation, I showed that it is the affect stathmin depletion has on MT stability 
that leads cells to stall in G2.  By depolymerizing or simply lowering the amount of 
stable MTs back to control levels, I was able to successfully alleviate the G2 delay that is 
normally associated with stathmin depletion in cells lacking p53 (Carney and Cassimeris, 
2010).  Based on our results, I was also able to eliminate p27kip1 and STAT3, stathmin’s 
other binding partners, as participating in delaying the cells in G2 since their involvement 
would have yielded the opposite results.  Changes in MT stability are less significant 
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when p53 is restored, supporting the idea that depletion of stathmin and p53 leads to a 
greater change in the MT network. 
 
The results above are consistent with what is observed with other known chemotherapies.  
For instance, paclitaxel causes tumor cell death in mitosis due to an inability to both 
rearrange the MT array and progress through the cell cycle (Xiao et al., 2006).  However, 
unlike paclitaxel, which leads to a cell cycle block in mitosis (Rieder and Maiato, 2004) 
and eventual apoptosis, the depletion of stathmin initiates a cell cycle delay in G2 
(Carney and Cassimeris, 2010).  In order to determine both what MT stability is 
effecting, as well as, what pathways are leading the cell to delay will need more 
experimentation. 
 
Future Directions 
 
In chapter 2, I demonstrated that stathmin depletion in the absence of p53 leads to both a 
G2 delay and apoptosis, but I did not test how, or if, these two outcomes are connected.  
Two days after stathmin depletion a significant increase in the population of G2 cells was 
observed, which begins to drop as cells proceed to day three (Carney, B. and Cassimeris, 
unpublished).  On the other hand, apoptosis does not reach a significant level until three 
days after stathmin depletion (Carney and Cassimeris, 2010).  Based on this time line of 
events, I assume that cells begin to delay in G2 24-48 hours after stathmin depletion and 
only after this delay is apoptosis initiated.  Cell death only occurs when p53 and stathmin 
are both depleted and leads to a model (Figure 4.1) where stathmin depletion increases 
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MT stability causing a G2 delay before activating apoptosis.  Evidence from Sur et al 
(2009) supports the model that a G2 delay is followed by apoptosis.  Using an inhibitor 
against a G2 cell cycle activator, polo-like kinase 1, they showed that cells lacking p53 
were more sensitive to death after a stress that follows the arrest.  For simplicity in 
chapter 3, I decided to look at only the G2 delay, but these same experiments should be 
able to determine if apoptosis is linked to MT stability and if apoptosis follows the G2 
delay.  By using stathmin truncations, one could look at longer time course experiments 
to see if manipulating MTs allows cells to escape apoptosis, as well as the delay.  A 
short-term MT depolymerization, with nocodazole, to alleviate a G2 delay could possibly 
address whether the G2 delay and apoptosis are linked.  Unpublished data from our lab 
(Cassimeris, L., unpublished) shows that cells can slip out of G2 and into the next cell 
cycle prior to apoptosis (Figure 4.2).  Synchronizing cells before stathmin depletion could 
increase the number of cells delayed in G2.  After the delay is established, adding 
nocodazole will allow cells to progress into mitosis.  In order for cells to continue into the 
next cell cycle, nocodozale must be washed out shortly afterwards (3-5 hours).  
Bypassing this delay should not change whether cells activate apoptosis if the two are not 
linked, but will allow cells to continue to grow and proliferate for a longer period of time 
if there is a link between the processes.   
 
Similar to the Sur et al (2009) experiments discussed above, hindering progression into M 
phase by using inhibitors against proteins that control the G2/M transtition could 
determine if there is a link between the processes of G2 delay and apoptosis that I 
observe here.  Assuming the block created using such inhibitors could be reversed, this 
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arrest would mimic the affect of stathmin depletion on cell cycle progression.  If the 
processes of G2 delay and apoptosis are linked, then cells should begin apoptosis 
assuming the cell cycle delay is equivalent to the one induced when stathmin is depleted. 
 
If the G2 delay and apoptosis are not linked it would suggest that in the absence of p53 
and stathmin more then one pathway is activated.  These pathways would likely be 
initiated in a similar manner (increased stable MTs) but lead to distinct downstream 
phenotypes.  If this is in fact the case determining what signals are activating each branch 
of the pathway would be the next logical step.  
 
After determining if there is a link between the G2 delay and apoptosis, one could go 
about testing the models discussed in chapter 3.  For instance, in order to test if the signal 
to delay and/or kill the cells is relayed through an inability to breakdown the MT array, 
live cell imaging of stathmin depleted cells can be used.  Using a fluorescent marker of 
cell cycle progression, one could observe the duration required for MT disassembly in 
stathmin-depleted cells, compared to control treated cells.  If the rate of MT disassembly 
does not change, it is likely that the G2 delay is occurring prior to the breakdown of the 
interphase MT array and may be caused by the signal sequestering model instead of due 
to an inability to breakdown the MT array. 
 
Another possible involvement of the MT array would be if the increase in acetylated MTs 
that was observed functions as a signal itself.  Acetylation of MTs changes the way 
certain motors and other proteins bind to the MTs and therefore may be responsible for 
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the phenotypes observed when stathmin is depleted in cells lacking p53.  To test this 
model, one could change the state of MT acetylation by over-expressing the proteins that 
deacetylate MTs (HDAC6) (Warren and Cassimeris, 2007).  By artificially decreasing 
acetylation of MTs, but leaving them otherwise stable, one could test if the delay in G2 
and apoptosis is due to the acetylation or just the presence of stable MTs.  If a delay is 
present when acetylation is removed it would suggest the involvement of the sequestering 
model independent of MT acetylation state. 
 
In order to determine players that may act as signals on MTs, it would also be beneficial 
to determine what signals are initiating the cell cycle delay observed in stathmin-depleted 
p53 null cells.  Determining the pathway could narrow down potential connections 
between cell cycle delay and increased MT stability.  One pathway that is already being 
tested in our lab is the Rho dependent pathway that drives mitotic entry (Figure 4.3).  
Preliminary data from the lab (Caruso, V. and Cassimeris, unpublished) shows a 
significant decrease in the level of phosphorylation of three important players in this 
pathway, Aurora A, PLK1, and PAK1, when stathmin is depleted in p53 null cells.  In 
contrast, Wee1 and signals from the DNA damage pathway (Chk1) remain unchanged.  
The decrease in activation of enzymes downstream of RhoA supports the Rho pathway a 
as possible link between MT stability and cell cycle delay.  Activators of this pathway 
that bind to MTs, like GEF-H1 (which is inactive when bound), are therefore possible 
candidates that are causing the G2 delay. Once we determine possible links between cell 
cycle delay and MT stability, they can be tested directly by altering their levels in the cell 
without depleting stathmin.  It would also be beneficial to observe if the phosphorylation 
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states of these proteins change in the presence of p53.  Restoring p53 to these cells would 
allow us to see if a p53-dependent pathway is also involved.  In the presence of p53, no 
delay occurs.  Thus the decrease in the phosphoration states of proteins, such as Auroa A, 
are unlikely to occur. Since these experiments are being done in HeLa cells, one could 
utilize the HPV E6 siRNA to restore p53 and observe if there is a difference in the 
phosphorylation states of proteins in the Rho pathway when p53 is present.  If a 
connection is found between MT stability, p53, and this signaling pathway it would 
suggest a change in MT scaffolding, sequestering, or delivery is responsible for the cell 
cycle delay and apoptosis that is observed. 
 
So far, most of the experiments discussed here look at pathways associated with 
stathmin’s affects on MTs, but it is important to remember that p53 is also involved in 
this synergy.  In a normal cell, p53 has been shown to interact with both stathmin and 
MAP4 by down-regulating their transcription when p53 is active (Ahn et al., 1999). 
Although, this interaction between p53 and stathmin only occurs when p53 is active, it 
still shows that these proteins can function together.  To better understand the synergy 
observed here it would be beneficial to futher explore this interaction.  Perhaps, p53 and 
stathmin have a yet unknown association whether direct, or indirect, that can explain the 
phenotype observed here.  Examining p53’s roles in transcription, at the centrosome, and 
in metabolism may allow us to determine what about p53 mutation is leading to the 
synergy. 
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One such pathway leading to a cell cycle delay that I discussed in chapter 3 was 
glycolysis.  We already know that due to the Warburg effect the amount of glycolysis 
increases and the rate of oxidative phosphoryaltion decreases when p53 is lacking 
(Maddocks and Vousden).  Coupling that to changes in microtubule scaffolding due to 
stathmin depletion could cause a failure in glycolysis leading to a starvation state and 
may promote cell cycle delay and/or apoptosis.  This model should be relatively easy to 
test due to an increase in anaerobic metabolism even in the presence of oxygen.  This 
increases the amount of lactic acid produced by the cell (Delgado et al., 2010) thereby 
increasing its presence in the media.  By collecting the media, lactic acid levels can be 
compared and it can be determined if there is a decrease when stathmin is depleted in p53 
lacking cells compared to cells with stathmin or p53.  If a significant change in lactic acid 
levels is observed, then this pathway may also be involved.  Obviously, additional 
experiments would be necessary to test a metabolic model for synergy between stathmin 
and p53 reduction. 
 
Once we determine which pathways are involved and how the signal is relayed, we can 
determine better ways to activate the same pathways in cancer cells leading to cell death.  
My research should provide a good starting point in this process and may lead to 
improvements in cancer treatment in the future. 
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Figures: 
 
 
Figure 4.1:  Depletion of stathmin leads to G2 delay followed by apoptosis only in p53 
lacking cells.  This is a proposed model of how increasing MT stability can lead to 
apoptosis.  We know that increased stability leads to a G2 delay only when p53 is lacking 
and that it is only about 72 hours after stathmin depletion that cells begin to activate 
apoptosis.  But we still do not know if apoptosis follows the delay or if it is activated in a 
different pathway.  Based on the timing of events this pathway seems most likely.   
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Figure 4.2:  Following the G2 delay, cells slip into the next cell cycle before activating 
apoptosis.  This graph tracks individual cells to determines how long after the previous 
mitosis it is before they die.  Based on data from Kulartz and Kipper (2004) it appears 
that a majority of the cells die in G1 or S phase of the following cell cycle, assuming the 
cell cycle continues at the normal rate even though these cells never enter the next 
mitosis. 
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Figure 4.3:  This flow chart shows the core enzymes involved in mitotic entry.  Based on 
preliminary data, the Rho family of enzymes is a likely link between the mitotic stability 
and G2 delay we observe when p53 is lacking based on significant decrease in the 
phosphorylation (activation) states of its downstream targets, PAK1, Aurora A, and 
PLK1.  
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